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Abstract 
MICAL (from the Molecule Interacting with CasL) indicates a family of multidomain proteins conserved 
from insects to humans, which are increasingly attracting attention for their participation in the control of 
actin cytoskeleton dynamics, and, therefore, in the several related key processes in health and disease. 
MICAL is unique among actin binding proteins because it catalyzes a NADPH-dependent F-actin 
depolymerizing reaction. This unprecedented reaction is associated with its N-terminal FAD-containing 
domain that is structurally related to p-hydroxybenzoate hydroxylase, the prototype of aromatic 
monooxygenases, but catalyzes a strong NADPH oxidase activity in the free state. This review will focus on 
the known structural and functional properties of MICAL forms in order to provide an overview of the 
arguments supporting the current hypotheses on the possible mechanism of action of MICAL in the free and 
F-actin bound state, on the modulating effect of the CH, LIM, and C-terminal domains that follow the 
catalytic flavoprotein domain on the MICAL activities as well as that of small molecules and proteins 
interacting with MICAL. 
  
Abbreviations 
ABS, actin binding site; CasL, Crk (p38)-associated substrate-related protein; CC, coiled-coils; CH, calponin 
homology; CRMP, collapsin response mediator protein; DLS, dynamic light scattering; D-MICAL, 
Drosophila melanogaster MICAL; DTT, dithiothreitol; EHBP, Eps15 homology domain binding proteins; F-
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MICAL form comprising the MO, CH and LIM domains; MRTF-A , myocardin-related transcription factor-
A; MS, mass spectrometry; MST, Ste20-like kinase; NDR,  nuclear Dbf2-related; PAX5, paired box gene 
product 5; PHBH, p-hydroxybenzoate hydroxylase; pOHBz, p-hydroxybenzoate; PIP2, phosphatidylinositol 
bisphosphate; RBD, Rab binding domain; ROS, reactive oxygen species; SAXS, small-angle X-ray 
scattering; SDS, sodium dodecyl sulfate; SH3, Src homology domain-3; SRF, serum response factor . 
 
Highlights 
- MICAL is a multidomain flavoenzyme participating in actin cytoskeleton dynamics 
- The key role of MICAL in fundamental processes is being increasingly demonstrated 
- It catalyzes NADPH-dependent oxidase and F-actin depolymerizing reactions  
- Hypotheses on the mechanism of MICAL’s reactions are critically discussed  
- How MICAL may be modulated by its domains and interacting proteins is also reviewed  
 
  
3 
 
Introduction 
MICAL indicates a family of multidomain, mainly cytoplasmic, proteins, which participate in the control 
of actin cytoskeleton dynamics thanks to the unprecedented NADPH-dependent F-actin depolymerizing 
reaction associated with their N-terminal FAD-containing domain. The additional calponin homology (CH), 
LIM (from Lin-11, Isl-1 and Mec-3 gene products) and C-terminal regions, which are typical protein 
interaction domains, play modulatory roles.  
Since their discovery in 2002 [1, 2], a great deal of work has focused on MICALs biological function and 
regulation by combining genetic and cell biology approaches on model organisms and selected cell lines. 
The structural features of several isolated domains have been established. Several studies aimed to determine 
the catalytic properties of MICALs, especially the mechanism of the F-actin depolymerizing activity, as well 
as their modulation by the additional domains and interacting proteins.  
In this article, knowledge on the biological function of MICAL proteins and its possible implications in 
disease will be summarized. Next, structural information on MICALs will be briefly reviewed to provide a 
framework for the discussion of MICALs catalytic activities and their regulation, which will be the focus of 
this article. Due to the vast literature related to the topic, it will not – unfortunately - be possible to quote all 
relevant work. 
MICAL stands for the Molecule Interacting with CasL from the discovery of the first member of the 
family (MICAL-1) as an interactor of CasL in a human thymus library [1]. CasL (from Crk-associated 
substrate-related protein lymphocyte type) is also known as NEDD9 (from neural precursor cell expressed, 
developmentally down-regulated 9) or HEF1 (from human enhancer of filamentation 1) [3, 4]. It is a docking 
protein involved in signaling pathways related to T-cell differentiation, cell-cell junctions formation, cell 
migration in part in response to integrin activation and it is also associated with several cancer forms [4-6]. 
Shortly after the first report on MICAL-1 [1], studies in Drosophila melanogaster revealed that MICAL is a 
plexin interactor and participates in axon steering by mediating the repulsive signaling of extracellular 
semaphorins [2]. 
Correct axon navigation during development is under the control of a complex network of attractive and 
repulsive signals [7]. Among them are semaphorins, which form a broad family of membrane-bound and 
secreted proteins [8-11]. They have been originally discovered as repulsive cues in the axon growth process, 
but are now implicated in a variety of other processes related to cell proliferation, migration and 
differentiation not only in the nervous tissue, such as, e.g.: angiogenesis, cardiogenesis, immune cell 
differentiation and bone morphology [12-19]. In a simplified scheme to illustrate semaphorin action, binding 
of semaphorin to their plexin receptors on the axon growth cone determines recruitment and activation of a 
number of proteins, including small GTPases, the collapsin response mediator proteins (CRMP) and, as a 
novel member, MICAL. As a result, local disassembly of the actin cytoskeleton takes place with axon 
growth cone retraction, which is followed by regrowth upon the combined action of attractive and repulsive 
stimuli [11, 20-24]. 
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The initial studies also led to identify only one gene encoding MICAL in drosophila, but three genes 
coding for MICAL-1, -2 and -3 in vertebrates [1, 2, 25-28]. MICAL-like proteins (MICAL-L1 and MICAL-
L2), encoded by different genes, also exist [28, 29]. They also participate in actin cytoskeleton dynamics, but 
they lack the N-terminal flavoprotein domain so that their function is independent from NADPH-dependent 
oxidoreduction reactions. Whether some of their biological roles overlap with those of MICALs is not clear, 
but they seem mainly involved in endocytic recycling [29-31]. While it has been shown that semaphorin 3A 
activates MICAL-1 through its PlexinA receptor, it is not fully clear if all other MICAL forms respond to 
semaphorin-plexin interaction. Regulating pathways independent from semaphorins may also be operative 
for all MICALs as shown by the interaction between MICAL and MICAL-like forms with proteins of the 
Rab family [25, 26, 29, 31-39], guanidine exchange factors [40], beside the possible modulatory roles of 
CasL [1], CRMP [41, 42] and other proteins [43]. 
The fundamental finding that MICAL is essential for the transduction of semaphorin signaling in 
drosophila [2], thus, for the correct development of neurons, stimulated a series of studies that extended the 
role of MICALs to a wide range of processes requiring actin filaments dynamics, such as, e.g., formation of 
tight junctions, synapses and the organization of myofilaments (drosophila MICAL, [27]), dendrite pruning 
(MICAL-1, [44, 45]), vesicle trafficking ( MICAL-3, [33]), gene expression regulation (MICAL-2, [46]). 
Very recently, it has been shown that MICAL-1 is essential to complete cell division [32]. Reports that 
MICAL or MICAL-like proteins are involved in host defense from pathogen infection or infectivity have 
also appeared [47, 48]. It remains to be established if and how MICALs participate in the control of 
microtubules and intermediate filaments as suggested by its interaction with CRMP [21, 41, 42] and 
vimentin [1], respectively. 
Some of MICAL roles may not be related to its oxidoreductase activity as suggested for the anti-apoptotic 
function of MICAL-1. In this role it sequesters the nuclear Dbf2-related kinase (NDR1/2, [23, 43, 49]). Thus, 
it antagonizes MST1-induced NDR activation and, therefore, interrupts the apoptotic signal of MST (Ste-20-
like kinase). The interaction with CasL has also been proposed to sequester this protein from the integrin-
dependent pathway [1], but the observation has not been apparently followed up by further specific studies. 
Modulating MICALs function has been proposed to be beneficial to prevent or treat a broad range of 
diseases only in part paralleling the aim to interfere with semaphorin signaling, which are emerging as 
important therapeutic targets [9, 11, 50-52] . MICAL-2 isoforms found in prostate cancer cells have 
indicated a role of MICAL in tumor progression [53]. Unfortunately, the accession codes for such MICAL-2 
prostate variants (PV1, AB126828 and PV2, AB126829) appear to lead to the same nucleotide sequence that 
seems to encode a human protein unrelated to MICAL (BEN domain-containing protein 4 isoform a , 
NP_997289, 534 aa; http://smart.embl.de/smart/do_annotation.pl?DOMAIN=SM01025).  
However, increased expression of MICAL-2 was associated with the epithelial to mesenchimal transition 
in gastric and renal tumors that leads to metastasis formation, the cause of most of cancer-related deaths [54]. 
MICAL-1 seems to be associated with melanoma [49], but in a manner related to its anti-apoptotic role as a 
binder of NDR1/2 [43], while its contribution to the generation of oxidative stress was shown to be important 
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for invasiveness of breast cancer cells [55]. Down-regulating MICAL’s expression decreased the 
invasiveness phenotype of the cancer cells [54, 55]. MICALs may contribute to scar formation following 
spinal cord injury and modulation of its activity has been proposed to beneficial for the treatment of neuronal 
degeneration [56, 57]. Altered levels of MICAL have even been associated with epilepsy [58]. 
A thorough analysis of the wealth of information from genome sequencing and expression profiling 
seems missing, but it could be useful to clarify the correlation between specific mutations and the expression 
levels of MICAL (iso)forms with tissues distribution, developmental stage and disease. MICALs are 
expressed in most tissues with only partially overlapping patterns indicating that they all play roles in 
cellular plasticity, but may have different specific roles [19, 20, 23, 56, 59, 60]. In this respect, the function 
of drosophila MICAL in dendrite pruning was shown to be controlled by SOX14, which responds to 
ecdysone [44]. Correct splicing of drosophila MICAL appears to require a functional ubiquitin-proteasome 
system, suggesting that a similar mechanism is operative in vertebrates [45]. Human MICAL-3 expression 
was reported to be under the control of PAX5 (from Paired Box Gene 5 product) and binding motifs for 
several other transcription factors have been found upstream one of its potential [61] promoters. Interesting 
its pre-mRNA embeds microRNA648 that target endothelin-1 whose elevated levels induce pulmonary 
hypertension in sickle cell anemia [61], further increasing the interest in MICAL, but also further 
complicating the dissection of its biological roles. 
In this complex scenario, a contribution to the understanding of MICALs comes from in vitro structure-
function studies on isolated native and engineered protein forms. 
MICAL architecture: an overview. 
Sequence analyses revealed that the three MICAL forms (MICAL-1, -2 and -3) in vertebrates and the 
single MICAL form of the drosophila model organism are multidomain proteins. They are very similar to 
each other with respect to the sequence of the flavoprotein, CH and LIM domains, while the interdomain 
segments and sequences of the C-terminal regions are less conserved. Since detailed sequence comparisons 
have already been presented by us (Figure 4, [62]), only a schematic distribution of (sub)domains and 
fingerprints is shown here (Figure 1A) with details of representative protein sequences given as appropriate.  
All MICALs contain a conserved N-terminal region with sequence similarities with FAD-dependent 
enzymes of the oxidase/monooxygenase families (residues 1 – 489 of human MICAL-1, Figure 1). 
Determination of the three-dimensional structure of the mouse MICAL-1 N-terminal flavoprotein domain 
[63, 64] showed that it is similar to p-hydroxybenzoate hydroxylase (PHBH), the prototype of class A 
monooxygenases [65-68]. For this reason, the N-terminal flavoprotein domain will be indicated as MICAL-
MO, or MO from monooxygenase-like domain, instead of “redox”, “FAD”, and even “EN” used in other 
publications. This convenient acronym is not meant to imply that a hydroxylating reaction is actually 
catalyzed, as discussed below. 
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In MICAL-1 the MO domain is followed by the calponin homology (CH, residues ~510-613 for human 
MICAL-1) and the LIM domain (residues ~688-756, Figure 1). The C-terminal region contains a PPKP Pro-
rich motif for the interaction with the Src Homology 3 (SH3) domain of CasL ([1], residues 830-833 for 
human MICAL-1) and a Glu-rich region (residues ~866-880 for human MICAL-1) of unknown function. 
The regions predicted to form coiled-coils (CC) at the C-terminus (residues 918-1067) has now been shown 
to consist of three α-helices forming a rather flat surface and to serve for Rab binding [32, 69]. The C-
terminal region is believed to be the site, which is mainly responsible of the interaction of MICAL with 
several other proteins (e.g.: PlexA [2], vimentin [1], NDR1/2 [43], CRMP [41]). 
In MICAL-3 the LIM domain is conserved although it is separated from the CH domain by a protein 
fragment longer than the equivalent region in MICAL-1. In the C-terminal region, the Pro-rich region is 
conserved. A Glu-rich region is more extended than that of MICAL-1 (residues 910-1052) and the similarity 
is low. The motifs for the formation of CC are present, and they have also been shown to form the Rab 
binding domain [69]. The peptides connecting these potentially functional regions are longer than in 
MICAL-1. A bipartite RKRX(14) KRRK sequence (residues 663-683 of human MICAL-3) has been 
proposed to be a nuclear localization signal [46] conserved in MICAL-2 (see below). In MICAL-1 only a 
RSR motif is found at position 644-646. Accordingly, MICAL-3 was found in the nucleus of HEK293T 
along with MICAL-2 but not MICAL-1 [46]. However, MICAL-3 is also found in the cytoplasm where it 
may form complexes with Rab proteins [33] so that for this and the other MICAL forms the precise 
localization (or re-localization) in cell compartments still needs to be determined.  
MICAL-2 is similar in length to MICAL-1, but it differs from both MICAL-1 and MICAL-3 for the lack 
of the C-terminal region. The LIM domain is at the C-terminus of the protein, well separated from the CH 
domain. Motifs that may allow the formation of coiled-coils (or α-helices) have been found in the protein 
segment between the CH and LIM domains (residues 837 – 971 of human MICAL-2, [62]) but also in the 
1070-1124 region that follows the LIM domain. This region may be responsible of the binding of Rab1 
detected also for MICAL-2 [25, 26]. A PSPP motif, conserved within the MICAL-2 proteins (residues 899 – 
902 for the human species) may correspond to the PXXP motif that was identified as the SH3 domain 
binding site in MICAL-1 and MICAL-3. A RKRX(14)KRRRK bipartite nuclear localization signal was also 
found at position 660-681 of human MICAL-2 [46]. Accordingly, MICAL-2 partially localizes in the 
nucleus of HEK293T, COS7 and HeLa cells where it determines the nuclear actin levels and, as a 
consequence, modulates the transcription of genes (mainly involved in cell differentiation and motility) 
under the control of the serum response factor (SRF)/myocardin-related transcription factor-A (MRTF-A) 
complex [46]. 
Drosophila MICAL is much longer than vertebrate MICAL-1, -2 and -3 due to the different length of the 
poorly conserved interdomain regions. Its overall architecture is similar to that of MICAL-1 and MICAL-3, 
but it apparently lacks the Glu-rich region between the Pro-rich peptide and the C-terminus where motifs for 
CC formation are located. 
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General properties of purified MICAL preparations for in vitro studies. 
Various MICAL forms have been produced and purified in several laboratories for in vitro studies. Only 
in a few cases the preparations have been characterized in sufficient detail to provide a set of reference 
information on quality and general properties of the protein preparations across full-length and truncated 
forms and various laboratories. 
Early on, the mouse MICAL-1 MO domain has been produced in Escherichia coli by two laboratories 
that determined its structure [63, 64] revealing the similarity with PHBH. The mouse MICAL-1 MO was 
also used to demonstrate that this protein catalyzes a hydrogen peroxide-producing NADPH oxidase activity 
([63], see below). Drosophila MICAL forms comprising the MO domain (MICAL-MO or just MO) and both 
the MO and CH domains (MICAL-MOCH or MOCH) have been produced in E. coli and purified to study 
their NADPH-dependent F-actin depolymerizing activity [70-73]. However, it was only recently that lab 
protocols have been presented [74]. Mouse MICAL-1, and MICAL-2 MO and MOCH forms have been 
produced to study their in vitro actin depolymerizing activity [46, 75]. The structure of mouse MICAL-1 
MOCH has been recently presented [76] along with mechanistic information (see below). The CH and LIM 
domains of human MICAL forms have been isolated to determine their structures by NMR. Recently, 
various forms of the C-terminal regions of human MICAL-1 and -3 have been produced for the 
determination of their three-dimensional structure and to study their complexes with Rab proteins [32, 69]. 
The mouse MICAL-2 MO has also been produced in E. coli and characterized [77].  
The production and basic characterization of the full-length form of human MICAL-1, as well as of the 
progressively truncated variants lacking the C-terminal region (MOCHLIM), the LIM (MOCH) and the CH 
domain (MO) have provided a set of methods for the study of this class of enzymes and benchmark 
information [78, 79]. 
The human MICAL-1 forms were produced in E. coli cells [78, 79], like all other MICAL species. They 
are purified by combining metal-chelate, ion exchange and gel filtration chromatographies in quantities that 
now reach at least 0.5 mg/g of starting cell paste. Variations of similar protocols were successful for the 
production and purification of MICAL forms from different organisms (see above). The protein yield is 
similar to that reported for mouse MICAL-1 and MICAL-2 MO, but significantly higher than that reported 
for drosophila MOCH (2 mg from 45 g cells, [74]). The human MICAL-1 forms exhibit the yellow, orange 
or brownish color often reported for MICALs containing the MO domain (e.g.: [74, 77]). Accordingly, the 
absorption spectrum in the visible region (Figure 2) shows an absorption band at wavelength greater than 
500 nm, which may be attributed to the charge-transfer complex between FAD and Trp400 (Trp405 for 
MICAL2, [62]) observed in the mouse MICAL-1 MO crystal structures [63, 64], rather than the fact that “the 
protein backbone shields the FAD from absorbing light” as stated in [74]. 
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MICAL forms readily release the FAD coenzyme upon guanidine-, heat- or SDS-denaturation allowing 
for the determination of the extinction coefficient and stoichiometry of bound FAD. SDS-treatment offers the 
advantage of maintaining the denatured protein in solution [80], so that the removal of denatured protein by 
centrifugation described in [74] is not needed nor actually possible. 
 
Extinction coefficients at 458 nm of 8.1 – 8.9  mM-1cm-1 have been reported for human MICAL-1 forms 
[78, 79], and drosophila MICAL-MOCH [74]. The extinction coefficient of mouse MICAL-2 MO was 
slightly higher (9.8 mM-1cm-1, [77]) and the absorption maximum was at a lower wavelength (445 nm 
versus 458 nm). For practical purposes a common extinction coefficient at 458 nm of 8.1 mM-1cm-1 is used 
for all human MICAL-1 forms [78, 79]. Results consistent with the presence of 1 FAD and two Zn++ ions per 
protein molecule were obtained for all human MICAL-1 forms and for the MOCHLIM and full-length 
MICAL, respectively. Drosophila MICAL MOCH was reported to be isolated with precisely 1 mol FAD 
bound per protein molecule [74]. However, in this case protein concentration was determined from the 
absorbance at 280 nm and the extinction coefficient calculated for the apoprotein, which leads to 
overestimating MICAL concentration (see below). 
Determination of the stoichiometries of FAD bound to all forms of MICAL and of zinc ions bound to 
forms containing the LIM domain, as well as the calculation of turnover numbers, require an accurate 
determination of protein concentration. The use of the extinction coefficient at 280 nm calculated from the 
protein sequence with programs like the Protparam tool of the Expasy suite (http://web.expasy.org/cgi-
bin/protparam/protparam, [81]), which ignore the absorbance of the FAD coenzyme in the UV (see, e.g.: [74, 
76]) may lead to overestimating the concentration MICAL forms by up to 30% (see comments in [81, 82]). 
In Table 1 the extinction coefficients experimentally determined for human MICAL-1 forms at 458 nm are 
shown along with those calculated at 280 nm by adding the value obtained for the apoprotein and the 
extinction coefficient of FAD at 280 nm in diluted buffer at pH 7 (21 mM-1cm-1). The corresponding values 
of the guanidine-denatured protein species are also shown with the extinction coefficient of FAD at 280 nm 
calculated experimentally as 22. 7 mM-1cm-1.  
Human and mouse MICAL-1 MO and MOCH are monomeric in solution [63, 64, 76, 78, 79]. 
Accordingly, the CH domain of human MICAL-1 was monomeric [83, 84]. Human MOCHLIM behaves as a 
dimer at low protein concentration (0.5 mg/ml), but it tends to oligomerize at higher concentrations (Vitali 
and Vanoni, unpublished). Full-length human MICAL-1 seems to exist in solution as a mixture of compact 
monomers and dimers, as judged by combining analytical gel filtration, dynamic light scattering and small 
angle X-ray scattering (unpublished). Whether this property is biologically significant and is related to the 
presence of the LIM and/or of the C-terminal region still needs to be determined (see also below). The 
helical region at the very C-terminus of MICAL-1 is monomeric both in solution and in the crystal structure 
[32, 69]. On the contrary, the corresponding part of MICAL-3 forms dimers as described in the next section 
[69]. 
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Structural information on MICALs. 
The structure of mouse MICAL-1 MO was presented in two independent back-to-back papers in 2005 
([63, 64], Table 2, Figure 3). It revealed for the first time that the domain contains FAD and that it is 
structurally related to PHBH, the prototype of FAD-dependent aromatic monooxygenases ([65-68, 85] and 
references therein). In the light of its strong conservation, the mouse MICAL-1 MO can be taken as a valid 
model for the corresponding domain of all MICALs, although subtle differences may be the reason for some 
of the functional differences that will be discussed below. As for PHBH and related flavoenzymes, the core 
of MO is formed by a large domain (the FAD-binding domain, residues 1–226 and 373–484 with the mouse 
and human MICAL1-MO numbering) and a smaller one (residues 234–366) that we refer to as the cap 
domain for consistency with previous work [62, 86]. The connection between these domains is less complex 
than in PHBH involving β strands β9 ( residues 227–233) and β15 (residues 367–373, ), suggesting a greater 
conformational flexibility of MICAL-MO with respect to PHBH (Figure 3). MICAL MO lacks regions 
corresponding to the C-terminal dimerization portion of PHBH. Residues 1-71 [63] or 1-85 ([64], Figure 3) 
form a subdomain unique to MICAL, which precedes the core region. Here, several conserved basic residues 
(Lys-52, -61, -66, -69, and -86; Arg-35 and -70; His-11, -13, and -49) contribute, with other conserved 
residues of the FAD binding domain, to form a patch of basic electrostatic potential on one face of the 
protein (Figure 4A, circled). The latter has been proposed to be the docking site for an acidic protein partner, 
such as actin itself [64].  
Another positively charged region is found on the opposite face of the MO domain (Figure 4B, white 
star). It most likely marks the NADPH binding site on the basis of the overall similarity between MO and  
PHBH and of the presence of several conserved basic residues that in PHBH contribute to NADPH binding 
[63, 64] (see also the sequence analyses in [62]). The FAD coenzyme binds to MO in an extended 
conformation as found in PHBH (Figure 5). At variance with the structures of PHBH in the oxidized forms 
([65-68] and references therein), the “as isolated” MICAL-1 MO is in the “flavin out” rather than “flavin in” 
conformation (with the dimethylbenzene ring pointing towards the surface of the NADPH-binding region, 
Figures 3-5). The isoalloxazine ring of FAD (re-face) and Trp400 side chain are parallel and in close contact 
forming the charge-transfer complex that characterizes the MICALs spectra (Figure 2). The FAD/Trp 
charge-transfer complex is not shared with PHBH. Rather is reminiscent of enzymes of the 
ferredoxin:NADP+ reductase family [87]. NADPH-treatment of mouse MO crystals led to a form in which 
one of the two subunits of the crystallographic dimer (chain A) contained reduced FAD [64]. In the other 
subunit a mixture of oxidized and reduced species was observed. Reduction caused a conformational change 
that shifted FAD from an “out” to an “in” conformation due to a rotation of the C3-C4 bond of the ribityl 
side chain. It was accompanied by a 6.5° rigid body rotation of the “cap” with respect to the FAD binding 
domain with the β9 and β15 connection acting as a hinge (Figures 3-5). The switch from the “flavin out” 
(oxidized) to the “flavin in” (reduced) conformation also increased to some extent the size of the cavity in 
front of the isoalloxazine ring, where the active site should be on the basis of the similarity with PHBH [64]. 
Furthermore, inspection of the protein face opposite to that with the proposed NADPH binding site revealed 
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the formation of a small channel that connects the surface to the active site, so that the FAD isoalloxazine 
ring seems now accessible (Figure 4 C,D). Interestingly, the mouth of such channel and the immediate 
surroundings of the flavin isoalloxazine ring involve highly conserved residues [62], among which is the 395 
- 405 loop that contains Trp400 (Figure 3). These observations led Siebold et al. [64] to propose that a small 
molecule or, more attractively, a protein side chain could now access the MO active site from this side and 
be modified. The positive patch on the same side of the protein could help docking a hypothetical acidic 
protein substrate (e.g.: actin). Inspection of the region that should correspond to the MO active site revealed 
no evident similarity with PHBH or other well-characterized flavoenzymes. Thus, no further clues on the 
actual MO substrate and reaction mechanism were obtained [64].  
The mouse MICAL-1 MOCH structure in the “as isolated” (oxidized) form was recently determined 
(Table 2, Figure 6, [76]). Note that the 4TTT code for the “native 2” structure appearing in Table 1 of [76], 
which we identify in Table 2 as structure 4TXK from the description and the Protein Data Bank, seems to 
correspond to the “Crystal structure of an O2-tolerant [NiFe]-hydrogenase from Ralstonia eutropha in its as-
isolated form (oxidized state) – 3” (no accompanying publication). The structure of the MO domain is not 
altered in the presence of the CH domain [76]. At variance with previous analyses of the MICAL-1 MO 
structure [63, 64] and their direct inspection, the MO domain is now described as showing a “cavity that 
connects to the active site larger in MICAL-MO than in PHBH” so that it “could potentially accommodate a 
protein substrate” [76]. A “large opening” and a “small opening” that make the FAD coenzyme accessible 
from the surface [76] are now defined along with a “catalytic loop” in proximity of FAD isoalloxazine ring 
in the “in” conformation and being formed by conserved residues. If our reading is correct the “catalytic 
loop” is the 395 –405 loop containing Trp400 in MICAL-1 (Trp405 in MICAL-2, Figures 3, 6). Its 
conservation indicates that this loop is indeed important. For example, Trp400 should reposition to allow for 
hydride transfer from NADPH to the flavin during the catalytic cycle (see below). However, its precise 
involvement in catalysis remains to be established. The “large opening” should correspond to that on the MO 
face where the NADPH binding site is likely located. Here, the NADPH nicotinamide ring should reduce the 
flavin when in the “out” position by analogy with PHBH. The “small opening” mentioned in [76] should be 
the channel that connects the surface to the active site in the reduced protein form ([64], Figure 4). However, 
it cannot be ruled out that through even limited protein motions the MO active site may become accessible to 
small molecules. Overall, the cavity in proximity of the flavin isoalloxazine ring, where the active site should 
be located by analogy with PHBH, appears rather small in all structures available (see also Figure 4C, D of 
[64]). 
The structure of the isolated MICAL CH domain was determined by NMR ([83] and several depositions 
in the PDB that are not accompanied by publications, Table 2). Sequence and structural comparisons led to 
the conclusion that it belongs to the Type 2 class. CH domains are found in several actin binding proteins 
where they serve to bind G- or F-actin [28, 88-92]. In spite of the conservation of motifs identified as actin 
binding sites, actin binding proteins typically contain two tandem CH domains. The C-terminal CH domains 
(defined as Type 2 or CH2 domain) do not bind G-actin and are not sufficient to bind F-actin. Rather, as 
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exemplified by α-actinin, it is the N-terminal Type 1 CH domain (or CH1 domain) that is mainly responsible 
of binding to the filament [88-92]. Accordingly, [83] did not observe CH binding to G- or F-actin. 
The high resolution structure of mouse MICAL-1 MOCH ([76], Table 2, Figures 6 and 7) confirmed the 
assignment of the CH domain to the Type 2 class and confirming the high similarity with α-actinin (PDB 
2EYI, [93], 4D1E [94]) CH2 domain, taken as a well-characterized example of actin binding proteins 
containing tandem CH domains. The 19 residues connecting the MO and CH domains were not visible in the 
crystal structure and multiple options were found for the structure of the MOCH protein [76]. Association of 
the MO and CH domain of the same polypeptide chain was done thanks to small-angle X-ray scattering 
experiments (SAXS) in solution leading to the model in Figure 6. A similar model was obtained by us with 
the human MICAL-1 MOCH by SAXS (unpublished). The MOCH structure shows no contacts between the 
domains in agreement with the similar spectroscopic and kinetic properties of the human MICAL-1 MO and 
MOCH forms [78, 79]. The residues corresponding to the actin binding site and a potential 
phosphatidylinositol bisphosphate (PIP2) binding site are shown in Figures 6 and 7. Interestingly, to our 
knowledge the interaction between MICAL and PIP2, which could function as a biologically relevant 
regulator [95], has not been studied yet. 
The role of the CH domain in MOCH has been explored through a series of kinetic studies that will be 
discussed below [76, 79]. Interestingly, the mouse MICAL-1 MOCH structure was used for in silico docking 
experiments to generate a model of the MOCH/F-actin complex [76], which will be discussed later in 
conjunction with the presentation of the reaction of MICAL in the presence of actin filaments. 
The structure of human MICAL-1 LIM domain has also been determined by NMR (Table 2, Figure 7). 
This domain is formed by two tandem zinc fingers and is found in a broad family of proteins that participate 
in cytoskeleton organization, signal transduction, cell adhesion, gene expression regulation [28, 96-99]. Little 
is known about its precise function in MICAL and MICAL-like proteins. From experiments in which various 
forms of MICAL were expressed in cell lines it may be important for the interaction with some MICAL 
protein partners such as, e.g.: CRMP proteins [41]. As an alternative, it may have a role in organizing the 
other MICAL domains. Whether it is fully responsible of the partial dimerization we observed in full-length 
MICAL (see above) or it participates in the so-called autoinhibition of MICAL exerted by the MICAL’s C-
terminal region [41] still needs to be established.  
In this respect, the initial observation that MICAL is recruited and activated by binding to semaphorin-
activated PlexA through its C-terminal region led to the hypothesis that this part of the protein plays an 
important role in stabilizing an inactive conformation of MICAL in the free state. Inhibition would be 
relieved when this region is engaged in interactions with other protein (the cytoplasmic side of PlexA, CasL , 
proteins of the Rab family or even NDR1/2). This hypothesis was strongly supported by the experiments of 
Schmidt et al. [41] with studies in selected cell lines and cell extracts and, later, was confirmed with purified 
proteins [32, 79] 
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The C-terminal region of MICAL-1 and -3 are conserved within each protein class. They share, as 
common features, the Pro-rich and Glu-rich regions mentioned above and motifs for the formation of CC. As 
mentioned before, MICAL-2 is organized differently with the protein ending after the LIM domain. 
However, a Pro-rich region and a motif consistent with the potential formation of helical structures was 
identified in the region between the CH and LIM domains, and the short segment after the protein C-
terminus may also form a helical structure (Figure 1, [62]). 
Our understanding of this part of MICAL has made progress since the recent publication of the structures of 
its C-terminal region where consensus sequences for CC formation were found [32, 69]. 
The C-terminal part of human MICAL-1 (residues 918-1067 [32, 69]) and the corresponding regions of 
human MICAL-3 (residues 1841-1990, [69]) were produced along with several variants [32, 69]. The 
corresponding fragments of human MICAL-cL (a MICAL-like protein containing only the C-terminal 
region) and of EHBP-1 and -2 (from Eps15-homology domain binding proteins-1 and -2), which were 
identified by sequence analyses were produced and analyzed as well [69].  
These proteins were found to be sufficient for binding several proteins of the Rab1 (Rab1a, Rab1b and the 
related Rab35) and Rab8 (Rab8, Rab10, Rab13 and Rab15) family of small GTPases. But the stoichiometries 
and binding affinities differed (see below). Thus, the domain will be called RBD for Rab binding domain to 
facilitate the presentation. 
The structure of the human MICAL-1 RBD was solved in complex with two copies of Rab10 ([69], Table 
2) and in the isolated form ([32], Table 2). The MICAL-1 RBD per se is monomeric and forms three α-
helices arranged to yield a compact curved surface ([32, 69], Figure 8). Only a few fragments in the N- and 
C-terminal part as well as in the loops connecting the helices are disordered. The complex between MICAL-
1 RBD and Rab10 (a member of the Rab8 family) showed the two Rab binding sites inferred from binding 
studies in solution with Rab8A that led to identify a high affinity site (Kd ~50 nM) in the first part of the 
RBD and a lower affinity site (Kd in the low µM range) in the second part. Accordingly, one Rab10 molecule 
mainly binds to residues of helix 1 and helix 2 (in part) in the first half of MICAL RBD and the second to 
helix 3 and helix 2 (in part) at the C-terminus (Figure 8).  
The RBD of MICAL-3 ([69], Figure 8) forms dimers with each subunit being similar to the MICAL-1 
RBD monomer [69]. The two copies of MICAL-3 form a central 4-stranded coiled-coil composed of α-
helices 2 and 3 of each monomer flanked by α-helices 1 on both sides. Interestingly, such intersubunit 
interactions overlap with the second (C-terminal, low affinity) binding site of MICAL-1 RBD, which is also 
observed in MICAL-cL in complex with  several Rab proteins ([69], Table 2). This finding explains why the 
RBD of MICAL-3 migrates in gel filtration as a dimer, but incubation with Rab8 seems to generate a 
complex involving one molecule of MICAL-3 RBD and 2 molecules of Rab8. Furthermore, there is an 
excellent match between the residues that appear to be essential for Rab35 binding [32] and those in the 
second Rab binding site of the Rab10/MICAL-1 complex of Rai et al. [69]. 
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Consistent with the presence of two Rab binding sites in the RBD of MICAL-1 and MICAL-3 is the 
formation of a ternary Rab8:MICAL-1:Rab6 complex, which was detected in cells [33].  
Further work is needed to fully explain the molecular reasons of the different specificity of the Rab 
binding sites. However, it has been established that the N-terminus of Rab seems important, as well as the 
presence of GTP that stabilizes the active conformation of Rab. On the contrary, the prenylation state of Rab 
does not seem to influence its interaction with MICAL’s RBD [32, 69]. The structural work also revealed 
that the two halves of the RBD of human MICAL-1, MICAL-3, MICAL-L1, MICAL-L2, MICALcL and 
also EHBP1, EHBP1L1 and C16orf45 (encoding an unknown protein) seem to be derived from each other 
through gene duplication, thus generating the family of bivalent MICAL/EHBP Rab binding (bMERB) 
domains as defined in [69] (Figure 9). 
An attempt to gain information on the region between the LIM and RBD of human MICAL-1 was done in 
preparation of this review using the Robetta web server (http://robetta.bakerlab.org/, [100]). Robetta 
correctly identified and modelled all MO, CH. LIM and Rab binding domains for which structural 
information is available. Region 779 – 907 was detected as an independent domain and it was modelled 
using the structure of a DNA polymerase III, γ subunit-related protein (tm0771) from Thermotoga maritima 
msb8 at 2.00 Å resolution (PDB ID: 2GNO) as template suggesting that it is an α/β globular subdomain. 
However, the sequence similarity with DNA polymerase γ subunit, which is important as it forms the sliding 
clamp of DNA polymerase and, interestingly, has ATPase activity, is very low. 
The high resolution structure of full-length MICAL has not been presented yet. However, with methods 
for its production and purification available it is likely work in that direction is in progress in several 
laboratories. Information on the structure of human MICAL-1 forms is being acquired also in our laboratory 
by solution studies by small-angle X-ray scattering in collaboration with the Svergun’s group [101-103]. 
 
Catalytic and mechanistic properties of MICAL forms. 
Nadella et al. [63] were the first ones to show that mouse MICAL-1 MO exhibits a strong NADPH-
dependent H2O2-producing NADPH oxidase activity (Figure 1B). Later, the Terman group demonstrated the 
NADPH-dependent F-actin depolymerizing activity that makes MICALs unique among actin binding 
proteins [70]. These seminal findings were followed by a variety of studies with different approaches by 
different groups with results that have led to sometimes significantly different conclusions. The biological 
effects of the NADPH oxidase activity of the free enzyme, which produces a reactive oxygen species (ROS), 
need to be precisely established. Whether the enzyme switches from a NADPH oxidase (in the free state) to a 
hydroxylase (when F-actin bound) that modifies specific actin residues or the actin depolymerizing activity 
is mediated by H2O2 produced by the NADPH oxidase reaction is a matter of debate. While there is general 
agreement on the fact that the C-terminal region of MICAL-1 and -3 is crucial for the switch from an 
“autoinhibited” to an active MICAL form, the precise properties of the “autoinhibited” form require further 
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investigation. The role of the other domains in promoting MICAL autoinhibition or activation still needs to 
be elucidated. Furthermore, it is not clear if all proteins that bind to the C-terminal region of MICAL (CasL, 
the cytoplasmic side of semaphorin-activated plexin, Rab, and even NDR that make MICAL function as an 
anti-apoptotic factor) stabilize the active form of MICAL. The CH domain was postulated to promote 
MICAL/F-actin interaction based on the fact that several F-actin binding proteins contain CH domains. 
Whether the hypothesis is supported by experimental evidence will be discussed. Whether MICAL’s reaction 
causes F-actin severing or dissociation of actin monomers from the filament ends is also under discussion. It 
still remains to be determined where other MICAL interactors (e.g.: CRMP) precisely bind, and if they may 
be also substrates or activators of MICAL. A precise understanding of MICAL’s mechanistic properties 
would also help the search of inhibitors as leads for novel drugs. Also this issue requires further work. 
In this section an attempt will be made to summarize the experimental evidence available on mechanistic 
aspects of MICAL and the various theories. Efforts to reconcile some discrepancies in the literature will also 
be made with the aim to contribute to the understanding of how these complex enzymes may actually work 
in vitro and in vivo. 
The NADPH oxidase activity of MICAL. 
Nadella et al. [63] demonstrated that mouse MICAL-1 MO catalyzes a NADPH oxidase activity by 
assaying H2O2 production in a coupled assay with horseradish peroxidase (HRP) and Amplex Red. The 
reported apparent kcat and Km for NADPH (Km,NADPH) value were 77 s-1 and 222 µM, respectively, calculated 
by varying NADPH concentration at fixed (atmospheric) oxygen concentration at 25°C in 20 mM Hepes 
buffer, pH 7.0, containing 100 mM NaCl. Human MICAL-1 MO was confirmed to catalyze a NADPH 
oxidase reaction with apparent kcat of ~ 3 s-1 and Km, NADPH of ~ 20 µM in the same buffer, but in the absence 
of NaCl (Table 3, [78]). The differences in Km,NADPH could be readily justified by taking into account the high 
sensitivity of human MICAL-1 MO to the ionic strength of the assay medium and also to the type of anions 
present [78]. With human MO (and the other MICAL forms), increasing ionic strength has a moderate effect 
on kcat, but leads to significant drop of kcat/Km,NADPH due to an increase of Km, NADPH, a property that actually 
reinforces the similarity with PHBH [104]. The almost 20-fold difference in kcat between the mouse and 
human properties may be rationalized by taking into account artifacts arising from the coupled assay with 
HRP and Amplex red [78] and by reanalyzing the raw data reported in Figure 5 of Nadella et al. [63]. 
NADPH was found both to inhibit the HRP reaction and to lower the total amount of H2O2 that could be 
quantified [78]. On the other hand, the rate of NADPH oxidation (as measured by absorbance changes at 340 
nm) was increased by HRP, Amplex Red (or o-dianisidine) and H2O2 ([78], and unpublished observations). 
Figure 5 of [63] shows spectra recorded at different times during an assay done in the presence of 0.1 mM 
NADPH and 6 nM mouse MICAL-1 MO, HRP and Amplex Red. If our calculations are correct, analysis of 
the raw data leads to an initial velocity (expressed as v/E) of ~13 s-1 (from the absorbance changes at 340 
nm) and of ~ 5 s-1(from the absorbance changes at 560 nm and 570 nm due to Amplex Red oxidation). The 
latter v/E value is close to that measured with human MICAL-1 MO (~ 3 s-1, Table 3). The origin of the 
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initial velocity value of approximately 0.11 µM NADPH oxidized per second shown in the inset of the figure 
at 100 μM NADPH [63] is not clear. It would translate in a v/E of 18 s-1 at 6 nM enzyme. Interestingly, 0.11 
roughly corresponds to the change of absorbance of Amplex Red during the first minute of reaction shown in 
the figure. The same laboratory now reports a kcat of 0.68 s-1 and a Km,NADPH of 28.8 µM for the same mouse 
MICAL-1 MO [76]. These values, which were obtained by directly monitoring NADPH oxidation at 340 nm 
(in the absence of reaction components other than buffer, NADPH and oxygen), are also unexpected. The 
quoted Km,NADPH is much lower than that expected by taking into account the fact that these assays were 
carried out in the high ionic strength buffer used to stabilize F-actin (F-buffer, 5 mM Tris/HCl, pH 8.0, 
containing 50 mM KCl, 2 mM MgCl2 , 1 mM ATP and 1 mM DTT). For comparison a Km,NADPH in the range 
of 500 µM was measured with human MICAL-1 MO in a similar buffer due to a combination of ionic 
strength and pH effects (Table 3, [78, 79]). The reported kcat value of mouse MO (0.68 s-1) is also 
approximately 5-6 fold lower than the corresponding value obtained with human MICAL-1 MO (~3 s-1). An 
attempt to rationalize these discrepancies will be done in the next section in conjunction with the description 
of MICAL activity in the presence of F-actin.  
The NADPH oxidase activities of full length human MICAL-1 protein of truncated forms progressively 
lacking the C-terminal region and the LIM domain (indicated as MICAL, MOCHLIM and MOCH, 
respectively) was studied in comparison with that catalyzed by the corresponding isolated MICAL-1 MO 
[78, 79]. As summarized in Table 3, the CH, LIM and C-terminal domains lead to a progressive increase of 
the apparent Km,NADPH, which seems to reflect the changes of the overall protein charge as the acidic CH (pI, 
4.6), LIM (pI, 5.3) and C-terminal regions (pI, 5.2) are added to the basic MO domain (pI, 9.1) in agreement 
with the know importance of electrostatics for NADPH binding to enzymes of the PHBH family. The 
apparent kcat values of the MO, MOCH and MOCHLIM forms are similar to each other. On the contrary, the 
kcat of the full-length protein is only ~10% that of the other forms confirming that the C-terminal domain 
inhibits the catalytic activity of the MO domain [41], but with purified protein [79]. All MICAL forms are 
very sensitive to the ionic strength of the medium and the identity of anions present, which mainly cause an 
increase of Km,NADPH. This property reinforces the similarity between MICAL-MO and PHBH, but also 
complicates kinetic analyses. For example, the pH profiles of the apparent steady-state kinetic parameters of 
the NADPH oxidase reaction had to be determined in a mixed buffer that minimized the effect of different 
anions and maintained the ionic strength low and constant throughout the explored pH interval [78, 79] 
(Figure 10). All curves were complex. kcat/Km,NADPH and 1/Km,NADPH values decreased from high values as the 
pH increased in a biphasic fashion. The shape of the curves most likely reflected the overall charge of the 
protein forms as a function of pH, rather than the effect of the protonation state of specific groups on the 
parameters [79]. In particular, the pH profile of 1/Km,NADPH is reminiscent of the 1/Kd,NADPH profile 
determined in PHBH [104] further reinforcing the similarity between MICAL MO and PHBH. The kcat 
profiles of MO and MOCH were similar to each other. kcat increased from a low non-zero value at low pH to 
a maximum at about pH 8 and then decreased to another non-zero value at high pH, perhaps indicating a 
change of the rate determining step of the reaction, which still needs to be explored. Fitting of the curve 
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suggested the presence of a group with pKa of 6-6.5 that needs to be deprotonated and of another with a pKa 
of 8.5 -9 that needs to be protonated to reach maximum values of kcat. Inspection of mouse MICAL-1 MO 
structures did not allow to identify any candidate for the observed pKa values, which are similar to those 
found in the kcat/Km,NADPH and 1/Km,NADPH profiles (Figure 10). Among residues in proximity of FAD, which 
marks the active site, only His126 may exhibit a pKa of 6-6.5. This residue is conserved in all MICAL MO 
and may stabilize the “flavin in” conformation through hydrogen bonds between its main chain atoms and 
the isoalloxazine N(3) and O(4) atoms (Figure 5). The local charge may influence the interaction. Arg121 
and Asp393 interact with the ribityl side chain (Figure 5). They may also contribute to the stabilization of the 
flavin in or flavin out conformation, and, therefore, influence the turnover rate. However, their pKa values 
cannot be readily identified with those that allowed to fit the pH profile of kcat with MO and MOCH. Spectra 
of human MICAL-1 MO and MOCH samples diluted in buffers at pH between 5 and 9-10 did not show any 
change except for evident signs of protein denaturation at pH above 8.5 – 9 ruling out that the protein overall 
charge or that of selected residues affects the stability of the FAD/Trp400 charge-transfer complex [79]. 
With MOCHLIM, kcat values increased from low values at pH 5, which were similar to those observed with 
MO and MOCH at the same pH, to a constant value at pH 6 to 9, similar to the maximum kcat value obtained 
with MO and MOCH. The kcat of full-length MICAL decreased from a high value at pH 5 to constant values 
in the explored pH range, which was limited by a combination of low activity, high Km,NADPH and protein 
stability. For this protein form the increase of kcat at low pH may reflect the loosening of the interactions 
between the MO domain (pI, 9.1) and the C-terminal region (pI, 5.2 ) due to the decrease of negative charge 
of the C-terminal region. However, the kcat value remained low indicating that if the increase of kcat at low 
pH is related to the titration of acidic regions of the protein, its isoelectric point should be well below 5. The 
Glu-rich portion of the C-terminal domain preceding the RBD of MICAL-1 may have a pI as low as 3.7 
(calculated for the 858-900 region of MICAL-1). 
The rate of reduction by NADPH of human MICAL-1 MO was also studied directly by rapid reaction 
kinetics under anaerobiosis in 20 mM Hepes/NaOH buffer, pH 7.0, 10% glycerol [78]. No reaction 
intermediates could be detected by comparing absorption changes at different wavelength. Complete FAD 
reduction took place in a single phase at a limiting rate of ~3 s-1 with a Kd for NADPH of 56 µM. Both 
values matched well the steady-state kcat and Km,NADPH values once the presence of 10% glycerol in the 
stopped-flow experiment was taken into account. Thus, the rate of enzyme reduction by NADPH, which in 
the stopped-flow experiment is independent from protein concentration determination, and may also detect 
the presence of enzyme forms exhibiting different activities, appears to fully limit turnover. 
The study of solvent viscosity effects both highlighted the presence of a rate determining conformational 
change in the enzyme reductive half reaction and helped to clarify the possible origin of the low kcat of full-
length MICAL [79]. The solvent viscosity effect on kcat/Km,NADPH was greater than one for all MICAL forms 
detecting a conformational change between NADPH binding and either flavin reduction by NADPH or 
NADP+ release from the reduced enzyme whose rate is relatively slow and contributes to the value of this 
parameter. The decrease from ~ 2.7 (MO), ~2.3 (MOCH), ~1.8 (MOCHLIM) and ~1.7 (MICAL) correlates 
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well with the increase of Km,NADPH that partially “suppresses” the effect. Indeed, for a large Km value the 
parameter would be determined by diffusion of NADPH towards the enzyme active site and the value would 
be 1. By analogy with PHBH, several conformational changes may take place during the MICAL MO 
catalytic cycle [65, 67, 68]. In a minimal scheme for MICAL, one conformational change could take place 
prior to flavin reduction, i.e.: Trp400 must probably move away from the position observed in oxidized MO 
to allow the correct positioning of NADPH nicotinamide ring for hydride transfer (Figure 5). Upon reduction 
the switch from the flavin out to the flavin in conformation must take place. NADP+ is a competitive 
inhibitor with respect to NADPH with a Ki of 77 µM [78] and titrations of MICAL-MO with NADPH 
indicate that the reaction equilibrium lies towards products with a Keq of approximately 0.59 x 106 for the 
overall equilibrium between oxidized MO and NADPH and reduced MO and NADP+ [78]. For all these 
reasons the working hypothesis is that the solvent viscosity effect on kcat/Km,NADPH detects the repositioning 
of Trp400 in order to allow the NADPH nicotinamide ring to approach flavin N(5) position. In the light of 
the match between kred in the stopped-flow and kcat, and the absence of detectable intermediates, the solvent 
viscosity effect of 1 on kcat likely indicates that a high solvent viscosity effect due to the relatively low rate of 
the conformational change preceding hydride transfer is offset by the fact that also hydride transfer is rate 
determining. The similar values of the solvent viscosity effects on kcat and kcat/Km,NADPH for the four MICAL1 
forms indicate that the relative magnitude of the steps of the reaction catalyzed by the MO domain is 
unchanged in the presence of the CH, LIM and C-terminal regions. Thus, with the information that kcat for 
MO, MOCH and MOCHLIM are very similar, it could be concluded that the low kcat value of full length 
MICAL is likely due to the fact that it reflects the presence of a fraction (~10%) of enzyme in a fully active 
conformation in equilibrium with a fully inactive form (~90%). If the high Km for NADPH reflected the 
overall charge of the protein, one would expect that full length MICAL in the active conformation exhibited 
a Km, NADPH as high as that of MOCHLIM, thus in the 0.3 – 0.5 mM range, but a kcat of approximately 3 s-1. 
Rapid reaction studies of the isolated half reactions of the various MICAL forms could be very informative. 
These studies have been limited so far by their tendency to aggregate at low ionic strength at the high 
concentration required for stropped-flow work. The need to include salt to avoid aggregation leads to high 
Km (Kd) values for NADPH so that complete analyses become difficult. 
A rapid reaction (stopped-flow) approach was mainly used to study mouse MICAL-2 MO [77]. The rate 
constant for enzyme reduction by NADPH, which occurred without detectable intermediates, was 0.07 s-1 
and the Kd for NADPH was 0.5 – 0.9 mM with the enzyme in 20 mM Hepes buffer, pH 8.0 and 4 °C. These 
results indicated that mouse MICAL-2 catalyzes NADPH oxidation at a much lower rate than the 
corresponding MICAL-1 form, a fact that has been qualitatively confirmed later [46].The Kd for NADPH 
was also high. The studies of mouse MICAL-2 MO also determined that the enzyme, like PHBH, transfers 
the 4-proR hydrogen from NADPH to the flavin; the kinetic deuterium isotope effect on the isolated 
reductive half reaction was 4 ruling out that a conformational change rather than hydride transfer could 
contribute to kred. A mid-point potential of the FADox/FADred couple of -240 mV was determined in 20 mM 
Hepes buffer, pH 8.0. It is more negative than the estimate of the corresponding value of ~ - 0.15 V for 
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human MICAL-1 MO at pH 7 [78]. The different mid-point potentials of the bound FAD may even explain 
the approximately 50-fold difference in reduction rate between MICAL-1 and MICAL-2 MO domains. 
The recent publication of methods to produce drosophila MICAL MOCH was not accompanied by a 
kinetic characterization of the catalyzed reaction [74]. From the data presented in Figure 3C of the same 
paper, the NADPH oxidase reaction appears slow (v/E, 0.018 s-1 at 100 µM NADPH, pH 8.0, with 600 nM 
enzyme).  
From a biological point of view, the NADPH oxidase activity of full-length MICAL may be sufficiently 
high to generate H2O2 that may act as a second messenger and could modulate the activity of other proteins 
through oxidation reactions, especially if the MICAL’s activating proteins determine where and when H2O2 
is produced. Furthermore, the high Km,NADPH suggests that the local concentration of NADPH determines the 
rate of H2O2 production assigning another potential regulatory role to this compound [105, 106]. The 
importance of redox regulation for cytoskeleton proteins and their organizers is known (see, e.g., [107-109]). 
Increased levels of ROS have been directly correlated with those of MICAL-1 and -2 in normal and cancer 
cells [41, 54, 55, 59]. Furthermore, it has been proposed that MICAL’s H2O2-producing NADPH oxidase 
reaction regulates the biological activity of CRMP2 [42, 107, 110], a member of the CRMP family of 
important regulators of the cytoskeleton and also mediators of semaphorin signaling, which interact with 
plexin receptors ([21, 41]; see below). Whether and how the NADPH oxidase activity of MICAL-MO is 
implicated in the F-actin depolymerizing reaction that makes MICAL unique among regulators of 
cytoskeleton dynamics is discussed in the next section. 
MICAL and F-actin. 
Since the discovery that MICAL participates in the transduction of the signal initiated by semaphorin 
binding to their plexin receptors, which results in local actin cytoskeleton disassembly, the hypothesis that it 
functioned as an actin-binding protein destabilizing the actin filament was made. The essentiality of the 
integrity of the N-terminal flavoprotein domain for the function was also inferred from the “loss-of-function” 
phenotype obtained by expressing variants in which all the three glycine residues of the GXGXXG motif in 
the Rossman fold for FAD binding were substituted by Trp residues. This rather drastic mutation is 
commonly used in ex-vivo and in vivo studies to establish the involvement of MICAL’s catalytic activity in a 
given function. The finding that the flavoprotein domain is structurally similar to PHBH [63, 64] and that it 
catalyzes a NADPH-dependent F-actin depolymerization [70] soon led to the hypothesis that MICAL 
disassembles F-actin by oxidizing an actin side chain and, eventually, that MICAL MO domain, as a member 
of the PHBH family, switches from an H2O2-producing oxidase activity, in the free state, to the specific 
hydroxylation reaction of its “authentic substrate” (Figure 1B). The bound authentic substrate would both 
control the reaction mechanism and enhance the enzyme catalytic efficiency. Mass spectrometry analysis of 
mammalian and drosophila actin that had been re-purified by ion exchange chromatography after incubation 
with drosophila MICAL MOCH showed that actin molecules had been oxidized by incorporating two 
oxygen atoms [71]. Among actin residues, only Met44 and Met47 were found to be oxidized to presumably 
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yield methionine sulfoxide. Testing of the behavior of MOCH with actin Met44L and Met47L variants 
showed that intactness of Met44 was crucial in order to observe NADPH-dependent MICAL-mediated actin 
disassembly [71]. The Met residues belong to actin D-loop at the interface between monomers in the 
filament (see, e.g.: [111]). These residues are at a critical position in the filament and are also particularly 
sensitive to oxidation [112]. It was later shown that R specific methionine sulfoxide reductases (mammalian 
MsrB, [75] and the drosophila homolog SelR [72]), but not the enzymes specific for the S isomer, reversed 
the modification of both actin Met residues demonstrating that Met44 and Met47 had been converted to 
methionine sulfoxide and indicating that only the R stereoisomer of methionine sulfoxide was generated at 
actin positions 44 and 47 by the MICAL reaction. Thus, the released modified actin monomers could be 
repaired, in vivo, by R-specific methionine sulfoxide reductases [113]. By direct observation of actin 
filaments that had been treated with MICAL, it was also concluded that MICAL severes them leading to 
actin fragments, which would then disassemble releasing monomers [71, 73]. Very recently, the modification 
of Met44 and Met47 (the latter residues being sometimes neglected in the discussion of mechanistic models 
of MICAL reaction with actin) was confirmed by observing protection of actin from subtilisin cleavage and 
using antibodies specific for the methionine sulfoxide derivative of actin [73]. The drosophila MICAL-
modified actin monomers were found to be actually still able to polymerize, but with slower kinetics and 
higher critical concentration for the initial nucleation events as compared to native actin [73]. By studying 
the NADPH-dependent actin depolymerizing activity of drosophila MICAL-MOCH in the presence of 
cofilin it was also proposed that Met44 (and Met47) oxidation of actin catalyzed by MICAL makes the 
filament more susceptible to the severing activity of cofilin so that – in vivo - MICAL and cofilin can 
cooperate in F-actin disassembly. From the resistance of actin to subtilisin digestion it was also concluded 
that full modification of actin Met by drosophila MOCH took place during the first minute of incubation, 
while disassembly was significantly slower in the absence of cofilin. In these interesting experiments the 
MICAL MOCH reaction was apparently quenched at different incubation times by adding NADP+ and 
kabiramide C (to sequester actin monomers). Whether NADP+ addition (1.5 mM) is sufficient to block the 
NADPH-dependent MOCH reaction has not been shown. For human MICAL-1 MO NADP+ acted as 
competitive inhibitor with respect to NADPH, but the Ki was high (1.7 mM) in the presence of 0.1 M NaCl. 
Other methods may be more efficient to block the reaction like the glutamate synthase-catalyzed conversion 
of NADPH into NADP+ used in [78]. However, that filament disassembly is slower than chemical 
modification by MICAL was independently confirmed by monitoring single actin filaments in a microfluidic 
set-up [32]. Fremont et al. [32] directly observed that human MICAL-1 forms cause the NADPH-dependent 
depolymerization of actin filaments by accelerating the release of monomers from their ends. Thus, a 
severing activity of MICAL could not be confirmed not even reproducing the experimental set up described 
by [71, 73]. The rate of monomer release with MICAL MOCH (600 nM) from the filaments increased during 
the first 2 minutes of treatment and reached a plateau value of 50 actin monomers released per second, a 
value 5-10- fold higher than that measured in the absence of MICAL, or NADPH. Interestingly, enhanced 
depolymerization was observed also after MICAL MO and NADPH were washed away from the capillary, 
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demonstrating that MICAL-oxidized actin filaments depolymerize faster regardless of the presence of the 
enzyme  
For the modification of actin Met44 and Met47 through a specific hydroxylase activity of the MICAL 
MO domain, the D-loop of actin, which is at the interface between monomers in the filament, should be 
“extracted”, enter the MO active site where the residue(s) would be stereospecifically hydroxylated and then 
converted to the R isomer of the methionine sulfoxide derivative. Eventually, the modified D-loop would be 
released to yield a destabilized filament that would disassemble spontaneously or, more rapidly, with the 
assistance of cofilin. A cooperative effect between MICAL and cofilin has been proposed previously [107]. 
However, in that case, MICAL was proposed to control cofilin by oxidizing it through the H2O2 released by 
its NADPH oxidase activity. Interestingly, cofilin did not prevent the interaction of drosophila MICAL 
MOCH with F-actin when the three proteins were present at similar concentrations, placing restraints on how 
MICAL MO may bind to F-actin.  
An interesting attempt to model the F-actin-bound MICAL was done using the crystallographic structure 
of mouse MICAL-1 MOCH [76]. In the simulation the MICAL CH domain was reportedly docked on an F-
actin dimer (PDB ID: 2ZWH, [114]) by mimicking the binding mode of α-actinin CH1 domain to F-actin as 
derived by (cryo)EM experiments (3LUE, [92]). Furthermore, the hypothesis was made that MICAL MO 
directly hydroxylates actin Met44 and converts it into methionine sulfoxide (see below for further discussion 
of this reaction). Thus, the simulations were performed by positioning the MO with the “large opening” 
towards the actin filament model. Then, a series of simulations was performed in which Met44 sulfur was 
constrained to get closer to the flavin C4a position until it reached a distance of approximately 3 Å [76]. In 
the resulting model it appears that MICAL MO interacts with F-actin close to the interface between 
monomers with the face where the proposed NADPH binding site is (Figure 11). The D loop of one actin 
monomer has been extracted from its original position and Met44 sulfur is in front of flavin N5 position. The 
Met44 sulfur seems to occupy the position of Trp400 CZ3 carbon atom, which must have been displaced 
along with the 395-405 loop (Figure 11, bottom panels). The authors [76] conclude that hydroxyl transfer 
from the 4a-hydroperoxide intermediate, which would be formed upon reaction of the reduced flavin with 
oxygen, could take place even when the flavin is in the “in” position.  
This model is very attractive, but it would rule out the equally attractive hypothesis of Siebold et al. [64] 
that NADPH and the (actin) substrate can bind in a non-mutually exclusive way to opposite faces of MO. 
Further work is certainly needed to fully reconcile the models above with the entire body of evidence 
available on the catalytic activities of MICAL forms, which is illustrated below. 
The rate of NADPH oxidation catalyzed by all MICAL forms tested increases significantly in the 
presence of F-actin but not in that of G-actin, as shown for the first time with human MICAL-1 MO ([62, 78, 
79], Figure 12). This is the behavior expected for a monooxygenase related to PHBH in the presence of its 
substrate undergoing hydroxylation. However, for a stereospecific hydroxylation reaction leading to 
formation of the R isomer of a methionyl-sulfoxide side chain, one would expect stereospecific modification 
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of one methionine residue (Met44) rather than two (Met 44 and Met 47) with equal efficiency. In any case, if 
Met44 and Met47 on actin D-loop were the substrates of a specific hydroxylase activity, one would expect a 
biphasic time-course of NADPH consumption. In a first phase NADPH should be rapidly oxidized in an 
amount corresponding to twice the total actin monomer concentration. Then, a second slow phase of 
NADPH oxidation would follow due to the NADPH oxidase activity observed in the absence of actin (Figure 
12). Instead, as initially shown for human MICAL-1 forms [78, 79] and later confirmed with other MICAL 
species [73, 76], fast consumption of all NADPH present is observed even when NADPH exceeds by far 
total actin monomers concentration. In some assays, the initial part of the curves describing the time-course 
of NADPH oxidation seemed to suggest the presence of a small initial faster rate [76, 78]. However, at least 
for human MICAL-1 forms, an initial fast phase is not always evident. Furthermore, it does not correlate 
with the initial F-actin concentration as expected for a “burst phase” in which the rapid and specific 
methionine hydroxylase activity would be followed by a slower NADPH oxidase reaction. On the other 
hand, at variance with the report of biphasic traces in the presence of actin [76], the traces shown for the 
reaction of mouse MICAL-1 MO and MOCH with NADPH (100 µM) and different F-actin concentrations 
show some biphasicity only with MOCH when F-actin is absent (see Supplementary Figure S4 of [76]). The 
difficulty to work with a viscous substrate like F-actin, in small reaction volumes (100 – 200 µl) due to the 
actin cost, is probably the reason for anomalies of the traces at the early reaction times one sometimes 
observes. 
The time-course and extent of NADPH consumption (Figure 12) could be interpreted in several ways [62, 
78, 79] and the recent data can help clarify the situation [32, 73]. In all cases, F-actin activates MICAL’s 
NADPH oxidoreductase activity (Figure 12, Table 3). MICAL MO properties predict that conformational 
changes take place as it cycles through the oxidized “flavin out” and reduced “flavin in” conformation. These 
conformational changes could be sufficient to mechanically destabilize the actin filament. The released 
monomers could repolymerize allowing for a steady-state level of filaments that would allow for multiple 
turnovers in a NADPH oxidase activity stimulated by F-actin. Thus, the MICAL-catalyzed actin 
depolymerization would be reversible, leading to the observed case of “substrate recycling” ([78], Figure 
12). According to such mechanical effect of MICAL, actin modification would be accidental making the 
hypothesis unlikely. As an alternative, the actin monomers dissociate from the filament because of oxidation 
through in situ release of H2O2 by the NADPH oxidase activity. If actin chemical modification were 
significantly faster than actin disassembly, the filament could last enough to activate MICAL reaction with 
NADPH for multiple catalytic cycles. The apparent case of “substrate recycling” would be operative also in 
this case. The same would hold if – beside the slow filament disassembly – one took into account the fact 
that oxidized actin monomers can reassemble, as recently shown [73]. In all these cases MICAL should 
function as a NADPH oxidase with F-actin playing a stimulatory role. According to another hypothesis, 
MICAL bound to actin could function as a hydroxylase (specifically converting Met44 and Met47 into the 
methionine sulfoxide derivatives at early reaction times) but also as a NADPH oxidase releasing H2O2 
directly on the filament (at a fast rate due to the activating effect of F-actin also on this activity).  
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To test this hypothesis the modification of actin that had been incubated with the human MICAL-1 forms 
and NADPH was analyzed by MALDI-TOF and mass spectrometry [79]. For these experiments the entire 
MICAL-treated actin population was analyzed by precipitating aliquots of the reaction mixture at different 
times (corresponding to different amounts of NADPH being oxidized). The analysis of MICAL-treated actin 
after the extensive manipulation described by [71] (buffer exchange by repeated dilution/concentration in 
centrifugal concentrators, followed by ion exchange chromatography and further concentration/dilution 
cycles for buffer exchange of the purest actin fractions) could have led to loss of unstable actin species and 
specific enrichment of others. Catalase was also included to scavenge any H2O2 released in solution although 
DTT is present in the F-actin stabilizing buffer used for the experiments [79]. Finally, actual catalytic 
amounts of MICAL forms were employed in order to complete the reaction in 20-60 min (e.g.: MOCH 10-30 
nM with ~ 20 µM prepolymerized actin) as opposed to the higher drosophila MICAL MOCH concentrations 
(600 nM with 1.1 µM actin for 90 min). 
Analysis of actin samples withdrawn at the early reaction stages had modification levels below detection, 
making unlikely a fast hydroxylation reaction of Met44 and Met47 followed by non-specific modification of 
other residues through in situ production of H2O2 by the NADPH oxidase activity. With samples withdrawn 
at longer incubation times, MALDI-TOF analyses of human MICAL-1-treated actin were consistent with 
oxidation of two-three residues in each actin molecule. Analysis of peptides obtained after proteolytic 
fragmentation of MICAL-treated actin showed modification of Met44 and Met47, but that also other residues 
had been modified with equal probability. The modified residues (Met 44 and Met47 on the actin 19-50 and 
40-50 fragments; Met269 or Met 283 on actin 255-282 peptide; Met355 or Trp340 or Trp356 on actin 329-
359 fragment and Met82 or Trp79 or Trp86 on the 69-99 peptide) are located near the interface between 
actin monomers in the filament (Figure 13). Among them Met269 and Met355 are closer to Met44 and 
Met47 than the other residues. 
These results are in contrast with those obtained with the drosophila [71] and mouse MICAL forms [75] 
with which only actin Met44 and Met47 were found to be oxidized. While it is difficult to explain the 
discrepancy, which may reside in the different experimental setup, the findings with the human protein are 
consistent with the fact that when MICAL MO binds to F-actin, most likely at the interface between 
subunits, the NADPH oxidase activity of the MO domain is stimulated leading to enhanced in situ 
production of H2O2 that would be able to modify several actin residues [79]. The geometry of the complex 
could even cause (stereo)specificity of chemical modification of actin residues. Release of MICAL from the 
filament with return to the basal NADPH oxidase activity would limit the number and type of modified 
residues. Furthermore, with a H2O2-mediated actin modification, a 1:1 stoichiometry of NADPH being 
oxidized per actin residue being modified would not be expected as some H2O2 molecules would not react 
with actin side chains. The lack of a severing activity of MICAL supported by [32], who observed that 
monomers are released from the ends of the actin filament, would be also consistent with the observed time-
course of NADPH oxidation in the presence of F-actin. With the reasonable assumption that MICAL 
recognizes a small region of the actin filament, a severing activity would lead to an increase of F-actin 
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fragments long enough to be recognized as MICAL substrates. Thus, NADPH oxidation should accelerate as 
the concentration of actin fragments increases over time. With a loss of monomers from the ends, the 
filaments concentration would remain essentially constant for a significant amount of time leading to the 
observed traces (Figure 12). 
The precise site where MICAL MO binds to actin is not known, although there is consensus on the fact 
that G-actin does not stimulate NADPH oxidation. Accordingly, G-actin was not oxidized when incubated 
with NADPH and the human MICAL-1 forms [79]. The MO domain is sufficient to bring about the actin 
chemical modifications, in vitro, ruling out that the CH, LIM and C-terminal regions of MICAL determine 
the specificity of the reaction [78, 79]. In the model of mouse MICAL-1 MOCH in complex with F-actin 
proposed by [76] (Figure 11), MO apparently interacts with actin with the face where the NADPH binding 
site should be located. Upon “extraction”, Met44 of the D-loop seems to occupy a position in front of the 
FAD isoalloxazine ring roughly corresponding to that of Trp400 in the crystallographic structures of various 
oxidized MICAL MO forms. Thus, actin and NADPH binding seem mutually exclusive events making it 
difficult to explain the activating effect of F-actin on the rate of NADPH oxidation, regardless of the reaction 
mechanism. In PHBH both p-hydroxybenzoate (pOHBz) and NADPH access the enzyme from the same side 
with pOHBz binding first. But pOHBz is a small molecule whose presence in the active site does not 
sterically interfere with NADPH binding and actually promotes the events that lead to flavin reduction and, 
eventually, the hydroxylation reaction. With the information available, it is difficult to conceive a model in 
which reduced and NADP+-free MO (or a stable 4a-hydroperoxide intermediate) binds to F-actin and only at 
this stage it completes the catalytic cycle. Reduced MICAL-1 MO is rapidly reoxidized in the presence of 
oxygen and no intermediate indicating a stable 4-hydroperoxide or hydroxyl intermediate could be observed 
even in the stopped-flow (Vanoni and Vitali, unpublished). Furthermore, it would be difficult to explain how 
F-actin both accelerates the rate of MO reduction by NADPH [76-79] and lowers its Km [78, 79]. The 
observation that MO reduction leads to the formation of a channel located on the opposite face of MO to the 
NADPH binding site ([64], Figure 4), and the suggestion of Siebold et al. [64] that this could be the face for 
MICAL-actin interaction would be consistent with the activating effect of F-actin on enzyme reduction by 
NADPH placing the actin and NADPH binding sites on opposite faces of MICAL. The channel that connects 
the protein surface to the active site, and other possible access points to the flavin through protein breathing 
motions, seems rather narrow. Thus, an amino acyl side chain could access the flavin and be modified, but 
also they may be the exit points of H2O2 produced by the NADPH oxidase activity of MICAL.  
The differences between an oxidase and a monooxygenase reaction depend on the fine modulation of the 
stability of the 4-OOH intermediate, which may be very subtle [115-117]. 
Regardless of the mechanism adopted by MICAL in its F-actin depolymerizing activity, kinetic analyses 
can be useful to determine how F-actin enhances NADPH oxidation and which is the role played by the CH, 
LIM and C-terminal domain in modulating the reaction. 
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The apparent steady-state kinetic parameters of the reaction of human MICAL-1 forms in the presence of 
F-actin were studied by monitoring the initial velocity of NADPH oxidation spectrophotometrically in the F-
actin stabilizing buffer (F-buffer, [78, 79], Table 3). In the absence of F-actin, due to the combination of the 
ionic strength and pH effects on MICAL forms, the Km, NADPH values measured in F-buffer are 5-20-fold 
higher than those measured in the standard assay buffer (20 mM Hepes/NaOH, pH 7.0), while the apparent 
kcat for NADPH is only marginally reduced (Table 3). In the presence of F-actin (2.4 – 4.5 µM) the catalytic 
efficiency (kcat/Km,NADPH ) of all species increased significantly due to both a drop of Km,NADPH values and an 
increase of kcat. Km,NADPH reached value as low or lower than those measured in the low ionic strength 
standard assay buffer. (Table 3). Thus, the MO domain seems to have become insensitive to the presence of 
the additional domains upon binding to F-actin. Differences in the kinetic parameters among the various 
species should not be overinterpreted due to the intrinsic difficulty of this type of assays. The apparent kcat 
values also increased 2-10-fold. By varying F-actin at NADPH concentrations that were 5-20-fold the 
observed Km,NADPH a hyperbolic increase of the initial velocity of the reaction was observed leading to the 
determination of an apparent Km for F-actin of 3-5 µM (as measured in terms of monomer concentration) for 
MO, MOCH and MOCHLIM, supporting the proposal that MO bound to F-actin is essentially insensitive to 
the presence of the other domains. Accordingly, the kcat for MO, MOCH and MOCHLIM reached similar 
values that were up to 10-fold higher than those measured in the standard buffer once the error associated 
with the determinations is taken into account, as well as the fact that a complete kinetic analysis was not 
performed due to the difficulty to precisely control the assay composition due to the use of F-actin, an 
intrinsically dynamic and heterogeneous substrate. With full-length human MICAL-1 the apparent Km,F-actin 
was 6-10-fold higher than that measured with the other forms (Table 3). It was interpreted to reflect the 
double equilibrium between the autoinhibited (inactive) and the fully active conformations, which lies 
towards the inactive form when full-length MICAL is free in solution (as estimated from the study of the 
NADPH oxidase activity) and that in which the protein in the active conformation binds F-actin with the 
same affinity as the other forms (Figure 14, [79]). Thus, it appeared that F-actin could be sufficient to 
stabilize the active conformation of MICAL by binding to the MO domain even in the absence of activators. 
However, the latter would promote F-actin depolymerization by increasing the local concentration of the 
MICAL form that is able to bind the filament. The effect would be a lowering of the apparent Km for F-actin 
to the value measured with the isolated MO domain. Once the MICAL’s MO domain is bound to actin, the 
affinity for NADPH drops and kcat increases. McDonald and Palfey [77] nicely demonstrated that mouse 
MICAL-2 MO is reduced by NADPH approximately 100- fold faster in the presence of F-actin (kred ~ 8 s-1 vs 
0.074 s-1) and that F-actin causes a 30 mV increase of the mid-point potential of MO-bound FAD from -240 
mV to -212 mV. If the greater tendency of FAD to be reduced by NADPH were shown at the transition state 
for hydride transfer, it would justify the increase of kred with mouse MICAL-2 MO and the 10-20-fold 
increase of kcat with all human MICAL-1 forms.  
The effect of F-actin on the steady-state kinetic parameters of mouse MICAL-1 MO and MOCH was also 
recently studied by varying NADPH concentration in the presence of different levels of F-actin [76] leading 
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to the conclusion that the CH domain has an important effect on the MICAL MO reaction in the presence of 
F-actin.  
In these experiments actin appeared to behave as non-essential activator. Accordingly, the data were fitted 
based on the scheme depicted in Figure 15. F-actin had no effect on the Km,NADPH of MO, which remained 
constant (28. 85 ± 2.4 µM) at increasing F-actin concentrations, but lowered the corresponding value of 
MOCH (5-6 –fold from 37.7 ± 8.4 µM to 6 ± 1.8 µM). The increase of the apparent kcat was lower on 
MICAL MO (4-5 - fold from 0.69 to 3.4 s-1) than with MOCH (~7 fold from 1.66 ± 0.31 s-1 to 12.3 ± 1.5 s-1). 
Furthermore, the Kd values for the complex between F-actin and the free oxidized MO or MOCH forms were 
calculated to be similar (9.3 ± 1.9 µM for MO and 10.5 ± 3.4 µM for MOCH). NADPH bound to MO had no 
effect on the affinity for F-actin, but the thermodynamic cycle of Figure 15 led to calculate a low dissociation 
constant of actin from the MOCH-NADPH complex (1.68 ±0.96 µM).  
Thus, it was concluded that the CH domain plays an important modulatory role on the reaction of MICAL 
MO with F-actin supporting proposals made when only MICALs primary structures were available. The 
structure of mouse MICAL-1 MOCH, as well as the model of MOCH in complex with F-actin (Figure 11), 
do not predict interactions between the MO and CH domain [76]. Thus, intermolecular interactions between 
the CH domain of one MOCH monomer and the MO domain of another MOCH – only in the presence of F-
actin - have been invoked to explain the different effects of F-actin on MO and MOCH [76]. In the crystal 
structure of MOCH, where the connection between MO and CH of the same molecule could not be seen, 
several possible mutual arrangements of the two domains were identified. Some of the conformations were 
ruled out by taking the account the length of the peptide connecting the MO and CH, one option was selected 
on the basis of SAXS measurements in solution (Figure 11). However, intermolecular interactions bringing 
the CH in contact with the MO domain are possible under conditions that would promote dimerization of 
MOCH, which has not been observed in solution yet. 
These conclusions fully agree with the idea that the CH domain has an important modulatory role of the 
MICAL-actin interaction, but are in contrast with the data shown for the corresponding human MICAL-1 
forms. In the light of the similarity between the human and mouse proteins this finding was unexpected, and 
a detailed analysis of the data available is worthwhile.  
In the experiments with mouse MICAL-1 MO and MOCH, F-actin was correctly treated as a non-
essential activator according to the scheme in Figure 15 because the rate of NADPH oxidation was 
significant in the explored NADPH concentration range also in the absence of F-actin. This is the first 
unexpected finding. In the absence of F-actin and in the high ionic strength F-actin stabilizing buffer (F-
buffer) Km,NADPH values in the range of 29-40 µM for MO and MOCH were measured. These values are 
surprisingly low because of the effect of ionic strength on both mouse [63] and human [78, 79] MICAL-1 on 
this parameter (compare the values in Hepes and F-buffer in Table 3 for the human forms). A Km,NADPH of 
222 µM was measured at pH 7 in the presence of 0.1 M NaCl for mouse MICAL-1 MO in the same lab [63]. 
The kcat values (0.69 ± 0.02 s-1 for MO and 1.7 ± 0.5 s-1 for MOCH) seem also low compared to that 
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previously reported for MO from the same lab (77 s-1, [63], even after recalculation leading to a value in the 
4-5 s-1 range, see before) and those obtained with the human proteins (Table 3). With the human proteins the 
activity of each one of the MICAL forms in the absence of F-actin was negligible in the light of the high 
Km,NADPH in F-buffer in the absence of F-actin and both the drop of Km,NADPH and increase of kcat in its 
presence (Table 3, [78, 79]). Thus, only the lower branch the scheme in Figure 15 would be operative. The 
analysis of the dependence of the reaction from NADPH concentration at different levels of F-actin was not 
done for the human proteins because of the difficulty to precisely control the reaction components under the 
experimental conditions, which appear to be similar to those adopted for the study of the mouse MO and 
MOCH forms. 
Assuming that the Km,NADPH with mouse MO in the absence of F-actin was underestimated, but not that in 
the presence of F-actin, a drop in Km,NADPH could be caused by F-actin also for mouse MICAL-1 MO. With 
F-actin and both MO and MOCH, there is a good agreement between the Km,NADPH measured in F-buffer in 
the presence of 2-4 µM F-actin with the mouse (20-30 µM) and human species (11-50 µM) . It should be 
noted that in [76] NADPH was varied between 3 and 100 µM with MO. At the lowest NADPH 
concentration, the initial velocity, which is usually measured within the first 10% of the reaction to ensure 
the measurement of initial velocities, should have been calculated where the absorbance change was only 0.3 
x 10-3 mM x 6.23 mM -1 cm-1 =0.001869 in 1 cm pathlength cells. The latter hypothesis can be made by 
comparing the traces of supplementary figure 4A for MO assays in the presence of 100 µM NADPH and 
different F-actin concentrations with the corresponding values of reaction velocity expressed as µM NADPH 
oxidized per second in panel C of the same figure [76]. For the corresponding measurements with MOCH, 
the NADPH concentration was varied between 10 and 150 µM so that the initial velocities of assays at the 
low NADPH concentration were also difficult to measure and true saturation with NADPH was not reached, 
at least in the absence of F-actin. The kcat measured with MOCH in the absence of F-actin (1.7 s-1) is similar 
to that measured with the corresponding human MICAL-1 form (Table 3), but the kcat with MO (0.69 ± 0.02 
s-1) is 100-fold lower than that reported by the same laboratory before (77 s-1, [63]) and approximately 4-5-
fold lower than that recalculated from the raw data shown in [63] and that measured with the human 
MICAL-1 MO (Table 3). The determination of protein concentration through the calculated extinction 
coefficient at 280 nm of the apoprotein could account for a 20-30 % overestimation of protein concentration, 
but this correction would not be sufficient to reconcile the data with the mouse and human MO’s or between 
the previous and current data with the same mouse enzyme form. Interestingly, when one plots the kcat values 
extrapolated at infinite NADPH concentration as a function of F-actin concentration using the data in Table 4 
of [76] (reported in Figure 16), it seems that the lowest F-actin concentration has no activating effect on the 
kcat of MO suggesting an interesting sigmoid behavior, which has not been discussed [76]. Unfortunately, F-
actin concentrations between 0 and 2 µM have not been explored with mouse MOCH to further clarify this 
aspect [76]. With the human forms, deviations from a hyperbolic dependence of v/E from F-actin 
concentration at low F-actin concentrations have been looked for, but not detected. A sigmoid behavior could 
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have even been due to spontaneous dissociation of F-actin upon dilution to concentrations closer to that 
critical for filament formation.  
Interestingly, if one disregards the kcat values obtained in the absence of F-actin, the dependencies of kcat 
on F-actin concentration with MO and MOCH follow the same hyperbolic trend with an apparent Km,F-actin of 
~1 µM. The kcat value calculated for MO in the presence of F-actin are also approximately 6-times lower 
than those calculated for MOCH (compare the left and right axes of Figure 16). If one made the hypothesis 
that 0.6 µM MO was used for the determination of kcat in the absence of F-actin (as stated in the methods 
section) but 0.1 µM was actually used in the presence of F-actin (as in the legend of Supplementary figure 
S4, [76]), the kcat values obtained at different F-actin concentrations for MO and MOCH would nicely 
overlap and both extrapolate to a maximum kcat at infinite F-actin of ~12 s-1 (Figure 16), which would reduce 
the discrepancy with respect to the data obtained with the human proteins (Table 3). Comparison of the 
values in Table 4, Figure 8 and Panel D of Supplementary Figure S4 of [76], however, leads to a puzzling 
finding. The initial velocity values calculated for assays done with 0.1 µM MOCH in the presence of 100 µM 
NADPH and varying F-actin (Supplementary figure S4, panel D) are different from those shown in Figure 8 
and in Table 4 (e.g.: at 8 µM F-actin the initial reaction velocity in panel D is 2.0 µM NADPH oxidized per 
second, which translates into a v/E of 20 s-1 for 0.1 µM enzyme in the assay (legend of Supplementary Figure 
S4) and 3.3 s-1 for 0.1 µM enzyme (methods, main text) versus a value of 8-10 s-1 read off the graph in 
Figure 8, main text).  
Indeed, more work needs to be done with all forms of MICAL available to establish the precise effect of 
F-actin on the reaction of MICAL forms. Proper handling of F-actin solutions and carefully controlling the 
actual reaction composition, especially when F-actin is the varied substrate, probably are the critical issue. 
Overall, there is consensus on the activating effect of F-actin and the time-course and extent of NADPH 
initially observed with the human and mouse MICAL-1, which leads to the proposal that MICAL 
disassembles F-actin through in situ H2O2 production via its NADPH oxidase activity. 
 
Modulators of MICAL 
Since the discovery of MICAL as a cytoplasmic multi-domain protein that is activated by semaphorin-
bound plexin, it has been proposed that the enzyme exists in at least two conformations: the inactive 
conformation typical of the free enzyme and the active conformation, which is stabilized when MICAL 
interacts with plexin with its C-terminal region. The “autoinhibited” model of free MICAL was further 
substantiated by Schmidt et al. [41] who demonstrated that MICAL-1 forms lacking the C-terminal region 
were “constitutively active” in cells also leading to enhanced H2O2 production, and also that the C-terminal 
domain most likely interacts with the protein fragment comprising the MO, CH and LIM domains [41]. 
Thus, the inactive state of MICAL could be depicted as a “closed” conformation and the active one as an 
“open” conformation (Figure 17). The comparison of the kinetics of the NADPH oxidase activity of the 
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human MICAL1 forms leads to propose that the “closed” inactive conformation represents approximately 
90% of the total protein in solution at neutral pH. Its amount may decrease at low pH as the acidic C-
terminal region is titrated. The “open” conformation representing the active form should have a kcat similar to 
that of the other forms (2-3 s-1) and a Km,NADPH of ~ 0.5 mM, which may also be higher in the cell depending 
on the actual ionic strength and anion composition. Only MICAL in the open conformation may bind to F-
actin through its MO domain. As a result F-actin could even be sufficient to shift the equilibrium towards its 
active form. The state of the filament depends on a variety of different factors so that it is also possible that a 
basal MICAL depolymerizing activity exists, but it is offset by prevailing filament polymerization as well as 
competition with one or more of the several actin binding proteins. Whether the “closed” and “open” 
MICAL forms can dimerize through the C-terminal domain (as observed for the RBD of MICAL-3) or other 
domains (e.g.: the LIM domain that stabilizes a MICAL-1 MOCHLIM dimer) still needs to be established.  
Whether and how MICAL-1 interactors modulate its activity is an area of research that has just started to 
be explored. Also the search of small molecule inhibitors has been done only in a few cases, but with scarce 
success so far. However, interfering with MICAL activity with small molecules or peptide analogs that 
would either block the activity of MO or lock MICAL in an inactive conformation could be of great interest 
in the light of the variety of important biological functions in which it is involved. 
Small molecule inhibitors of the NADPH oxidase activity of MICAL-MO. 
The identification of selective inhibitors of MICAL MO may be important for the understanding of its 
mechanistic features and, on a longer run, for drug design.  
(3)-epigallocatechin-3-O-gallate (EGCG) was proposed to be a selective MICAL MO inhibitor since it 
has been reported to inhibit PHBH [118] and it abolished the response of semaphorin A in dorsal root 
neurons more effectively than other antioxidants [2]. Indeed, Nadella et al. [63] observed strong inhibition of 
H2O2 production with mouse MICAL-1 MO in the coupled assay with HRP and Amplex red. EGCG behaved 
as a noncompetitive inhibitor with respect to NADPH and the calculated Ki was very low (2 µM). However, 
EGCG, as a catechol, is a potent H2O2 scavenger. Accordingly, by measuring the effect of EGCG on the 
NADPH oxidase activity of human MICAL-1 MO, as directly monitored by absorbance changes at 340 nm, 
EGCG was found to yield complex kinetic patterns and to be a more modest inhibitor ( Ki, 17 µM, [78]). 
Low concentrations of EGCG caused no changes in MICAL MO spectrum, but protein aggregation/ 
denaturation was observed at concentrations above 25 µM, thus explaining the complex kinetics [78]. 
Furthermore, the observed inhibition of semaphorin signaling observed with cells may be due to effects other 
than a specific inhibition of MICAL. Recently, it was confirmed that EGCG stabilizes the actin network in 
retinal ganglion cells, but the experiments ruled out a direct involvement of semaphorin and MICAL 
inhibition in the process [119]. Interestingly, the structures of EGCG and of xanthofulvin (SM-216289) are 
related. The latter is a natural compound that has been shown to interfere with the semaphorin signaling 
pathway and to promote neurons regeneration following spinal cord injury in rats [120] and also in other 
models [121, 122]. Thus, it cannot be ruled out that their mechanism of action is somehow related. These 
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compounds may act as general scavengers of ROS or they may bind to one or more proteins and even induce 
changes like the aggregation/denaturation observed with MICAL. We have not been able to find studies on 
the direct effect of catechols or related compounds on actin, independent from their antioxidant activity, 
which might help to shed light on some of these observations. 
On the basis of the similarity with PHBH, and assuming that MICAL MO could also be a hydroxylase 
oxidizing a protein side chain, several amino acids, peptides and benzoate derivatives were tested as effectors 
of the NADPH oxidase activity of human MICAL-1 MO [78]. Only benzoate derivatives had detectable 
effects behaving as competitive inhibitors with respect to NADPH. The Ki values decreased as the number of 
hydroxyl groups increased with a Ki of 0.1 mM for 2,4,6-trihydroxybenzoate. 
Interestingly, a peptide mimicking the actin D loop (synthetic actin “D-loop” peptide,  residues 39 to 52 
of actin) was synthetized and used in co-crystallization experiments of mouse MICAL-1 MOCH [76]. No 
peptide was found in complex with MOCH in the resulting crystals [76]. Since no comments were 
specifically made in the paper, one should assume that the same peptide was tested as a mouse MICAL-1 
MO or MOCH substrate or effector but no effect was detected. 
It has also been proposed that CCG1423 inhibits MICAL-2 both in cells and the purified MOCH form 
[46]. CCG1423 belongs to a series of compounds that are of interest for cancer treatment. They have been 
proposed to be inhibitors of the Rho family of small GTPases, but their precise mechanism has not been 
actually clarified yet [46]. CCG1423 inhibited the reaction of MICAL-2 MOCH, as monitored at 340 nm, but 
only in the presence of F-actin. Accordingly, CCG1423 had no effect on the NADPH oxidase activity of 
human MICAL-1 MO and MOCH forms (Vitali and Vanoni, unpublished), while its interference with the 
activity in the presence of other human MICAL-1 forms and/or F-actin has not been studied yet.  
 
Protein activators and inhibitors. 
Several proteins have been found to interact with MICAL, such as the already mentioned CasL, the 
cytoplasmic side of Plexin A, Rab proteins, CRMP and NDR1/2. Studies on the effect of these proteins on 
the modulation of MICAL activities have been limited so far to CRMP and Rab proteins. However, the 
availability of several MICAL forms and the growing structural information on protein fragments, may soon 
lead to thorough studies also using purified proteins. 
MICAL and CRMP.  
CRMPs (from collapsin response mediator proteins) are among the first proteins that were discovered to 
mediate cytoskeleton collapse following semaphorin signaling. They promote microtubules formation by 
interacting with tubulin dimers, and they are inhibited by phosphorylation [21]. It was shown that MICAL 
interacts with several members of the CRMP family in the cell [41], and that their interaction is promoted by 
semaphorin binding to their plexin receptors. Furthermore, CRMP1 and MICAL-1 seemed to cooperate to 
promote COS7 cell collapse even in the absence of semaphorin stimulation. By co-immunoprecipitation 
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from extracts of cells in which various combinations of CRMP and MICAL forms had been expressed, the 
strongest interaction was observed between full-length MICAL and CRMP-1, but the MICAL MOCHLIM 
region seemed sufficient. Overexpression of MICAL-1 MOCH and MOCHLIM forms led to an increase of 
H2O2 production as measured in cell extracts in the presence of NADPH, HRP and Amplex Red. Co-
expression of CRMP1 or addition of a C-terminally truncated (but native-like) CRMP1 form (residues 8-
525) to extracts of cells expressing MICAL-1 MOCH or MOCHLIM quenched the NADPH-dependent H2O2 
production suggesting that CRMP1 may be the substrate of the hydroxylase activity of MICAL-MO. 
Morinaka et al [42] and Gellert et al. [113, 116] reached the different conclusion that plexin-activated 
MICAL-1 may specifically promote the oxidation of Cys504 of CRMP2 through H2O2 production leading to 
CRMP2 dimerization through an intermolecular disulfide bridge. CRMP2 covalent dimers or the covalent 
complex between CRMP2-Cys504 and thioredoxin (or glutaredoxin) thiol would promote CRMP2 
phosphorylation by GSK-3β (glycogen synthase kinase 3). Phosphorylation of CRMP2 would inhibit its 
activity and lead to microtubules disassembly. It should be noted that inspection of the sequences of CRMP 
from different classes shows that Cys 504 is present only in CRMP2. Thus, the results with CRMP1 [41] and 
CRMP2 [42] may not be in contrast.  
The study of the interaction of human MICAL-1 forms with the same 8-525 CRMP1 form that led to 
quenching of the H2O2 produced by MICAL MOCH and MOCHLIM in cell extracts [41] was initiated in our 
laboratory (Vitali and Vanoni, unpublished) thanks to CRMP expressing plasmids kindly provided by Prof. 
Strittmatter (Yale University, USA). When equimolar amounts of human MICAL-1 MO or MOCH and 
CRMP1 (10 µM each) were mixed at low ionic strength, aggregation was observed with no indication of 
other perturbations of the MICAL MO spectrum. Dissociation was obtained by adding NaCl up to 0.1 mM 
indicating a non-specific electrostatic interaction. Accordingly, the NADPH oxidase activity of MICAL MO 
and MOCH was inhibited in a concentration dependent manner by CRMP1 at low ionic strength. Inclusion 
of increasing concentrations of NaCl in the assays relieved the inhibition. Interestingly, with 200 mM NaCl 
(MO) and 50-100 mM NaCl (MOCH) a small (10-20%) increase of activity was observed for CRMP 
concentrations up to 10-20 µM. At higher concentrations CRMP1 was again inhibitory. Mild activation 
followed by inhibition was also observed in the F-actin stabilizing buffer and with other MICAL forms. The 
increase of activity of MICAL MO and MOCH could be ascribed to a small Km,NADPH decrease. The 
interaction of MICAL MO and MOCH and CRMP1 was confirmed in the presence of F-actin in F-buffer. 
Here CRMP1 addition decreased the velocity of NADPH consumption by 10-20% and lost its effect at 
concentrations higher than 10-20 µM mirroring the trend observed in its absence. A Kd for the MICAL MO 
(or MOCH)/CRMP complex of 5-10 µM could be estimated from the kinetic data. A loose binding would be 
consistent with a modulatory role of CRMP-MICAL interaction. If one wanted to draw a scheme in which 
MICAL promotes microtubules disassembly by modulating CRMP activity, kinetic data would indicate that 
MICAL may function by physically sequestering CRMP1. In turn CRMP1 may promote H2O2 production by 
MICAL, but the stimulation would be very mild. However, CRMP would also compete – although very 
weakly - with MICAL for binding to the actin filaments somehow opposing cell collapse. These preliminary 
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studies tend to rule out that CRMP1 is a MICAL substrate or activator as observed for F-actin. However, 
they show that the availability of the series of well-characterized human MICAL-1 forms can help 
identifying and characterizing its effectors under controlled in vitro conditions. 
 
MICAL and Rab. 
Rab1 was shown to bind the C-terminal region of MICAL-1,-2, -3 in rat tissues and various cell lines [25, 
26]. An extensive search of Rab interactors [123] demonstrated that MICAL-1 (but surprisingly not MICAL-
2 and MICAL-3) and MICAL-like -1 and -2 proteins as well as MICAL-cL bind several proteins of the 
broad Rab family. They all bind Rab8A/B, Rab10, Rab13, and Rab15, which are phylogenetically similar, 
but only MICAL-1 bound Rab1A/B. This distribution suggested common (redundant) roles of various 
MICALs in intracellular membrane trafficking but assigned to MICAL-1 a function related to membrane-
associated signaling. In independent studies MICAL-3 was also found to bind Rab6 and Rab8 [33].  
Recently, Fremont et al . [32, 124] demonstrated that MICAL-1 is essential to complete cell division 
extending the number of essential processes in which MICAL-1 is involved and reinforcing the interest of 
MICAL as a drug target. Rab35, a member of the Rab1 family, was shown to both localize MICAL-1 in late 
cytokinetic bridges, and to activate its actin depolymerizing activity in the cell and in in vitro experiments on 
single actin filaments using microfluidics.  
An extensive sequence analyses led Rai et al. [69] to find a set of human proteins (EHBP1 and EHBP1L1, 
C16orf45) sharing with MICAL-1, -3 , MICAL-L1, MICAL-L2 and MICAL-cL the C-terminal region that 
was structurally characterized as the Rab binding domain. The interaction of these regions with members of 
the Rab8 (Rab8, Rab10, Rab13 and Rab15) and Rab1 ( Rab1a, Rab1 b, Rab35) families were studied by 
combining gel filtration chromatographies and isothermal titrations calorimetry. The various fragments RBD 
bound proteins of the Rab families with different stoichiometries and affinities, confirming possible in vivo 
differential control. Only one Rab1 molecule binds to MICAL-1 and MICAL-3 RBD with micromolar 
affinity (Kd, 2-3 µM), a result later confirmed by Fremont et al. [32] with Rab35 and MICAL-1 (Kd, 6-13 µM 
in a buffer with a triple ionic strength). Two molecules of Rab8 bound to the RBD of MICAL-1 and 
MICAL-3. The high affinity site (located towards the N-terminus) exhibited an affinity in the 30-50 nM 
range for the MICAL-1 and MICAL-3 RBDs, and the low affinity site a Kd 10-fold lower for MICAL-1 (~ 
0.5 µM) than for MICAL-3 (4.4 µM). 
A Rab binding site with a Kd in the nM range would suggest that Rab activation upon binding to GTP 
would recruit MICAL to the membrane where Rab is located. A looser interaction through the second Rab 
binding site would allow fine tuning of MICAL activity depending on the local activated Rab concentration 
and its changes over time [69]. That Rab35 activates human MICAL-1 towards actin depolymerization has 
been shown in single actin filament assays [32]. Ongoing work with the series of human MICAL-1 forms 
available in our lab is showing that indeed Rab8 (kindly provided by Drs Goody and Mueller, MPI, 
Dortmund) activates the NADPH oxidase activity of full-length MICAL-1, specifically increasing the 
observed kcat, but has a mild effect on forms lacking the C-terminal domain.  
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How the MICAL regions preceding its RBD affect binding stoichiometries and affinity for Rab and how 
Rab8 alters the kinetics of MICAL-1 in the presence of F-actin and the postulated equilibrium between the 
inactive (closed) and active (open) MICAL conformations (Figure 17) is being studied. 
 
Conclusions and future perspectives.  
The interest in MICALs is steadily increasing because of the finding of their involvement of a variety of 
essential biological functions in neuronal and non-neuronal cells. Interfering with their activity and 
activation may be of broad therapeutic interest. In spite of the fact that structural and mechanistic 
information is available, MICAL’s mechanism of action is still poorly understood. In particular, current 
literature leads to sometimes non univocal conclusions. 
There is general agreement that the MICAL MO domain catalyzes a NADPH oxidase reaction and that 
the catalytic activity of the MO domain is essential for the unprecedented NADPH-dependent F-actin 
depolymerase activity of all MICAL forms. The NADPH oxidase activity of MICAL, which is limited by 
enzyme reduction by NADPH, may be physiologically relevant depending of activating signals and local 
NADPH concentration. 
A great deal of work has been done to clarify the mechanism of F-actin depolymerization with two 
prevailing views. According to several results, MICAL MO switches from a NADPH oxidase (in the free 
state) to a specific actin Met44 and Met47 hydroxylase generating the R stereoisomer of methionine 
sulfoxide. This activity of MICAL is at the origin of the incorrect definition of MICAL as a methionine 
sulfoxide oxidase that appears in the annotations found in databanks.  
Met44 and Met47 modification would destabilize the filament and eventually lead to release modified 
actin monomers, which could be repaired by R-specific methionine sulfoxide reductases in the cell. MICAL-
dependent oxidation of actin residues would destabilize the fragment and make it more susceptible to the 
cofilin disassembly action, and possibly also alter the function of other actin binding proteins. At the time of 
writing, the Protein Data Bank contains an unreleased structure (5UBO) of gelsolin in complex with 
MICAL-oxidized actin, suggesting that a cooperative effect was also found between MICAL and this 
important regulator of actin cytoskeleton. 
Other results indicate that MICAL MO always catalyze a NADPH oxidase reaction, which is enhanced 
when it binds to F-actin through a significant increase of kcat and decrease of Km,NADPH. H2O2 released in situ 
by MICAL-MO could modify several actin residues at or near the interface between actin monomers with a 
destabilizing effect on the actin filament and, eventually, release of modified monomers (Figure 13). The 
extent and type of modifications would depend on the precise geometry of the complex between MICAL-
MO and F-actin.  
An argument against the hypothesis that F-actin modification is mediated by in situ release of H2O2 is the 
low reactivity of methionyl residues with hydrogen peroxide and the lack of effect of up to 40 mM H2O2 on 
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filament depolymerization [32, 71, 113]. The presence of DTT (typically 1 mM) in the F-actin stabilizing 
buffer is not sufficient to explain the lack of effect of such a high H2O2 concentration. However, it appears 
that the sensitivity of actin filaments to H2O2 greatly varies as a function of its precise status. For example, 
Lassing et al. [125] studied the H2O2-induced modification of cysteinyl residues in various G- and F-actin 
forms. With respect to F-actin, they showed that high H2O2 (20 mM) disassembles the filament with release 
of monomers (which can be monitored as a decrease of solution viscosity – in general -  and also of 
fluorescence, when pyrenyl-actin is used) but only causes fragmentation (as monitored by the decrease of 
solution viscosity, but not fluorescence) at a lower concentration (5 mM). Furthermore, removal of calcium 
ions below 1 µM appeared to make the filament insensitive to H2O2. No methionine oxidation was reported 
in these experiments, a finding that may be consistent with the low reactivity of methionine side chain with 
H2O2 discussed by Manta and Gladyshev [113] who report a second order rate constant for methionine 
oxidation by H2O2 of ~10-2 M-1 s-1. While the precise environment may strongly alter the methionine 
thioether reactivity, it should be noted that release of H2O2 from the enzyme active site through a NADPH 
oxidase activity may generate impressively high local product concentrations. For example, with a naif 
calculation, if one takes into account the Avogadro number (6.022 × 1023 molecules/mol), the presence of just 
one molecule of H2O2 (1.66 x 10 -24 mol) in a cube of 1 nm side (volume = (1 x 10 -9 )3 m3 x 103 l/m3 = 1 x 
10-24 l) corresponds to a H2O2 concentration of 1.66 M. For these reasons, further work is certainly needed to 
clarify the details of MICAL mechanism of actin filament disassembly. Unfortunately, carrying out the 
reaction in the presence of 18O2, and monitoring 18O incorporation in actin or release as water would not 
clarify the mechanism as the same result would be expected for a H2O2-mediated or a direct hydroxylation 
reaction, namely: one oxygen atom would be incorporated in the oxidized actin residue and the other in a 
water molecule. 
 
MICAL was proposed to severe F-actin as the first disassembly event [70, 71, 73], but recent data [32] 
showed that actin monomers are released from the filaments’ ends progressively shortening them. Filaments 
disassembly seems in all cases slower than their modification by MICAL [32, 73] explaining the peculiar 
time-course of fast NADPH oxidation that exceeded the amount of actin present (Figure 12) and is in 
contrast with the notion that MICAL MO acts as a specific Met44 and Met47 hydroxylase, but supports that 
actin disassembly is mediated by H2O2 production.  
Whether it will be possible to correlate the kinetic properties of MICAL in solution with information 
derived from direct observation of MICAL effect on individual actin filaments as in the microfluidics set-up 
shown in Fremont et al. [32] is not known, but it would be extremely interesting. Unfortunately, the 
fluorescence of FAD bound to MICAL MO is strongly quenched [78] so that direct observation of MICAL 
in action, at the single molecule level, does not seem straightforward. High resolution electron microscopy 
approaches may indeed help establishing how MICAL forms bind to F-actin and clarifying if F-actin actually 
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leads to MO activation even in the absence of ligands bound to other domains. The approach has been 
successfully applied to several actin binding proteins (see, e.g.: [111, 126-128]). 
Unfortunately, the availability of the structures of the MO, CH and C-terminal RBD of MICALs has not 
yet clarified whether MICAL MO always catalyzes a NADPH oxidase activity or if it switches to a 
monooxygenase reaction when actin-bound. The model of mouse MICAL-1 MOCH in complex with F-actin 
does not seem to be compatible with the observation that MICAL MO should simultaneously bind F-actin 
and NADPH to explain the activating effect of F-actin on the NADPH oxidation reaction (Figure 11). Very 
subtle differences distinguish monooxygenases and oxidases, and inspection of the MICAL MO active site is 
not sufficient to provide clear-cut answers. It would be actually very interesting to definitely prove that 
MICAL is an NADPH oxidase, which exploits the PHBH scaffold and the associated conformational 
flexibility for fine control of the reaction. Such conformational flexibility could actually be simply required 
to promote the interaction with the actin filament, which is conformationally heterogeneous [129].  
How the MICAL’s domains that follow MO modulate the catalytic activities also needs to be established. 
This issue is biologically relevant being linked to the in vivo regulation of MICAL activity. Only the C-
terminal region seems to have a clear role in stabilizing an inactive form of MICAL, which appears in 
equilibrium in solution with a fully active species. Whether the C-terminal RBD binds directly to the MO 
domain (perhaps preventing NADPH binding or the conformational changes that must take place during the 
catalytic cycle) or the other MICAL domains are important has not been clarified yet. The experiments of 
Schmidt et al. [41] would argue that the entire MOCHLIM fragment is required. Accordingly, the inhibitory 
effect of the MICAL-1 RBD on single actin filaments depolymerization was verified with a MICAL-1 
MOCHLIM form [32]. However, experiments with the different purified MICAL forms in solution would 
allow to determine stoichiometries and binding strength. Several proteins of the Rab family have been shown 
to bind to MICALs’ C-terminal RBD yielding 2:1 or 1:1 complexes depending on the Raba md MICAL 
RBD couple. That Rab binding to MICAL activates the protein has been shown by microfluidics observing 
the acceleration of degradation of individual actin filaments by full-length MICAL1 in the presence of 
Rab35, and also by us, studying the effect of Rab on the NADPH oxidase reaction of the full-length and 
truncated human forms (unpublished). Whether proteins other than Rab that interact with MICAL’s C-
terminal region stabilize the active “open” form of MICAL, and therefore, increase the NADPH oxidase 
activity will also need to be explored. The identification of the binding sites of each one of the MICAL’s 
interactors, as well as the study of how they alter the catalytic properties of the various enzyme forms may 
provide valuable information.  
Even if the mechanism of MICAL-catalyzed reactions and their control is far from being understood, 
there are sufficient information, methods and materials to develop selective inhibitors that could also serve to 
clarify structure-functions relations of MICAL in a synergistic way. 
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Table 1. Summary of general properties of human MICAL-1 forms 
 MO MOCH MOCHLIM MICAL 
Mass (calculateda) 55000 68338 86348 118920 
Mass (experimentalb) 54915 68222 87615 119084 
pI (calculated a) 9.1 7.7 6.7 6.2 
max, Vis (native) 458 458 458 458 
max, UV (native) 276 276 278 278 
UV/Visc 10.2 15.5 16.1 19 
ε458d, mM-1cm-1 7.9 ± 0.1 8.0 ± 0.2 8.3 ± 0.2 7.9 ± 0.7 
ε280, apoproteine, mM-1cm-1 68.87 89.84 99.81 124.79 
ε280, holoproteinf, mM-1cm-1 89.87 110.84 120.81 145.79 
ε280, holoprotein/ε280, apoprotein 1.3 1.23 1.21 1.17 
ε280, denaturedg, mM-1cm-1 91.57 112.54 122.51 147.49 
aMass calculated with the Compute pI/mw tool at www.expasy.ch by taking into account the post-
translational removal of the starting Met residue. bMass determined by MALDI-TOF. cRatio of the 
absorbance values at 276 or 278 nm and those at 458 nm of purified protein preparations (up to 9 
determinations; the associated error was less than 3%, [79]). dThe extinction coefficient of FAD bound to the 
native proteins and the FAD content was determined by either TCA or guanidine denaturation of the proteins 
(2-4 independent determinations, [79]). The values are similar to that previously measured with MO (8.1 ± 
0.2 mM-1cm-1 , 7 determinations, [78]), which, for practical purposes, is used to quantify all human MICAL-1 
forms. eCalculated for the apoprotein using the Protparam tool at www.expasy.ch by assuming that all Cys 
residues are reduced. fCalculated by adding the experimental extinction coefficient of FAD at 280 nm in 
diluted buffer at pH 7.0 (21 mM-1cm-1) to the calculated extinction coefficient of the apoprotein (previous 
row). gCalculated by adding the experimental extinction coefficient of FAD at 280 nm of FAD in 3 M 
guanidine/HCl in diluted buffer, pH 7.0 (22.7 mM-1cm-1) to the calculated extinction coefficient of the 
apoprotein. 
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Table 2. Summary of the access code of the structures of MICAL fragments deposited in the Protein Data 
Bank. 
PDB ID Protein Method Resolution, Å Ref. 
2BRA Mouse MICAL-1 MO MX 2 [63] 
2BRY Mouse MICAL-1 MO MX 1.45 [64] 
C2C4 Mouse MICAL-1 MO, NADPH-reduced MX 2.9 [64] 
4TXI Mouse MICAL-1 MOCH MX 2.31 [76] 
4TXK Mouse MICAL-1 MOCH MX 2.88 [76] 
2DK9 Human MICAL-1 CH NMR N/A [83] 
2E9K Human MICAL-2 CH NMR N/A - 
2D88 Human MICAL-3 CH NMR N/A - 
1WYL 
Human MICAL-1 CH as CH domain of NEDD9 
interacting protein with CH and LIM domains 
NMR N/A - 
2CO8 
Human MICAL-1 LIM as LIM domain of NEDD9 
interacting protein with CH and LIM domains 
NMR N/A - 
5LE0 Human MICAL-1 Rab binding domain MX 3.3 [32] 
5LPN 
Human MICAL-1 Rab binding domain in complex with 
Rab10 
MX 2.8 [69] 
5SZG Human MICAL-3 Rab binding domain MX 2.7 [69] 
5SZH Human MICAL-cL in complex with Rab1b MX 2.3 [69] 
5SZI Human MICAL-cL in complex with Rab8a MX 2.85 [69] 
5SZJ Human MICAL-cL in complex with Rab10 MX 2.66 [69] 
5SZK Human MICAL-cL in complex with Rab1bR8N MX 2.8 [69] 
-, no accompanying publication 
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Table 3. Steady-state kinetic parameters of the NADPH oxidase reaction catalyzed by human MICAL-1 
forms. Assays were carried out in 20 mM Hepes/KOH buffer, pH 7 (Hepes), or in F-buffer (9.5 mM 
Tris/HCl, pH 7.7, 45 mM KCl, 0.18 mM CaCl2, 0.18 mM MgCl2, 1.1 mM ATP, 1.3 mM DTT) in the 
presence of the indicated NADPH and F-actin concentrations or concentration ranges at 25°C. Apparent kcat 
and KNADPH values and their associated errors were determined by fitting the data to the Michaelis-Menten 
equation. The values have been taken from [78, 79] 
 
Buffer 
Protein 
nM 
NADPH 
μM 
F-actin 
μM 
kcat 
s-1 
Km 
μM 
kcat/Km 
s-1mM-1 
Hepes MO, 20 10-300 - 3.1 ± 0.1 19 ± 2 163 ± 18 
 MOCH, 60 10-600 - 2.5 ± 0.1 134 ± 5 18.5 ± 1 
 MOCHLIM, 60 30-1000 - 3.5 ± 0.1 230 ± 16 15.3 ± 1.2 
 MICAL, 690 100-800 - 0.28 ± 0.01 375 ± 33 0.75 ± 0.07 
       
F-buffer MO, 120a 10-300 - 2.6 ± 0.4 555 ± 118 4.6 ± 1.2 
 MO, 20a 10-300 2.4 12 ± 0.5 11.3 ± 2.7 1090 ± 260 
 MO, 20a 300 7 - 35 20 ± 1.0 4.7 ± 1.0 4149 ± 908 
 MOCH, 190 10-500 - 1.7 ± 0.1 459 ± 66 3.8 ± 0.6 
 MOCH, 3 10-200 4.2 21 ± 1.2 50 ± 8 423 ± 72 
 MOCH, 3 200 1 - 26 26 ± 1.2 2.7 ± 0.4 9487 ± 1468 
 MOCHLIM, 125 25-1000 - 4.3 ± 0.2 966 ± 66 4.5 ± 0.4 
 MOCHLIM, 12 20-200 4.4 6.4 ± 0.2 14 ± 1.6 448 ± 52 
 MOCHLIM, 12 200 2-24 15 ± 0.6 4.4 ± 0.5 3390 ± 378 
 MICAL, 1250 100-700 - 0.8 ± 0.5a 4652 ± 3202a 0.17 ± 0.15a 
 MICAL, 91 10-400 4.3 1.9 ± 0.1 29 ± 5 64.8 ± 12.2 
 MICAL, 91 200 3.8-23 7.8 ± 1.2 29 ± 7 276 ± 87 
athe parameters are poorly defined due to the high Km value for NADPH. 
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Figure 1. Domain organization in MICALs and general scheme of the reaction mechanism of flavin-
dependent monooxygenases. Panel A. The location of domains in human MICAL-1, -2, -3 and in drosophila 
MICAL (D-MICAL) is shown. Color code: MO, monooxygenase-like domain, residues 1-489, yellow; CH, 
calponin homology domain, 510-613, cyan; LIM, 688-756, fuchsia; P, proline-rich region containing the 
PXXP signature (in bold) for binding to Src-homology domain-3 (SH3) domains, 829-PPPKPPR-835, 
orange; E, Glu-rich region, residues 866-880 in MICAL-1, which is more extended in MICAL-3 being 
between residue 910 and 1052, red; RBD, Ras binding domain identified by [32, 69] in the region originally 
proposed to form coiled-coils also named bMERB from the bivalent MICAL/EHBP Rab binding domain 
[69], residues 918-1067. In MICAL-2 light grey bars indicate regions that may also form helical structures 
according to previous sequence comparisons [62]. The potential nuclear localization signals of MICAL-2 
(residues 660-681) and MICAL-3 (residues 663-683, [46]) are shown in dark purple. For this and the 
following figures, please refer to the on-line version for the color scheme. Panel B: A simplified scheme of 
the reaction mechanism of flavin-dependent monooxygenases that shows how the NAD(P)H-reduced flavin 
coenzyme can react with molecular oxygen and form a 4a-hydroperoxide intermediate, which evolves to 
yield oxidized flavin and hydrogen peroxide in the oxidase reaction or the hydroxylated substrate (SOH) in 
the monooxygenase activity. Production of superoxide is also possible, but has not been implicated in the 
case of MICAL. 
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Figure 2. Absorption spectrum of human MICAL-1. 
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Figure 3. Comparison of the structures of the mouse MICAL-1 MO in the oxidized and reduced forms. The 
structures of the mouse MICAL-1 MO in the “as isolated” (oxidized, PDB ID: 2BRY, panels A and B, [64]) 
and NADPH-reduced (2C4C, panels C and D, [64]) forms are shown in two orientations. The circle in panels 
A and C indicates the approximate position of conserved surface residues in the 1-85 subdomain that form a 
patch of basic potential (see also Figure 4). In panels B and D the protein is viewed from the NADPH 
binding site, as identified by similarity with PHBH.  Color code: MO domain: 1-85, blue; 86-227, 374-444 
and 235-366 in different shades of grey; β9 (227-233) and β15 (367-373), light green; the conserved 395-405 
loop is in red. FAD and Trp400 are also in cylinders. Carbon atoms are shown in green, nitrogen in blue and 
oxygen in red. This and all the other figures representing structural models were generated with CCP4MG 
[130]. 
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Figure 4. Comparison of the surface charge and FAD accessibility of the mouse MICAL-1 MO in the 
oxidized and reduced forms. The surface charge of the mouse MICAL-1 MO in the “as isolated” (oxidized, 
PDB ID: 2BRY, panels A and B, [64]) and NADPH-reduced (2C4C, panels C and D, [64]) forms are shown 
in the same orientations as in Figure 3. FAD is shown in cylinders. Carbon atoms are shown in green, 
nitrogen in blue and oxygen in red. The circle shows the patch of positive potential on one face of the 
protein; the white star indicates the conserved basic residues that identify the NADPH binding site by 
similarity with PHBH. In Panel C, FAD is now exposed to solvent due to the opening of the channel 
described by [64] upon reduction. The rectangle marks the areas that have been blown up in the right panels 
indicated with the primed letters. 
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Figure 5. Interaction of FAD in MICAL MO oxidized (flavin out) and NADPH-reduced (flavin in) state. 
Selected residues surrounding FAD have been extracted from the structures of “as isolated” (2BRY) and 
NADPH-reduced (2C4C) mouse MICAL-1 MO ([64]). Potential hydrogen bonds (< 3.5 Å) are in grey. 
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Figure 6. Structure of the mouse MICAL-1 MOCH fragment. The structure of the mouse MICAL-1 MOCH 
(PDB ID: 4TXI, [76]) is shown in two orientations as in Figure 3. Color code: MO domain: 1-85, blue; 86-
227, 374-444 and 235-366, grey; β9 (227-233) and β15 (367-373) strands, light green; the conserved 395-
405 loop is in red. CH domain: 507-614, cyan; conserved residues corresponding to the actin binding site are 
shown as cylinders with carbon atoms in grey; those of the potential PIP2 binding site are in cylinders with 
carbon atoms in green. FAD and Trp400 are also in cylinders. Carbon atoms are shown in green, nitrogen in 
blue and oxygen in red.  
 
 
 
Figure 7. The CH and LIM domains of MICAL-1. Left panel. Details of the CH domain of mouse MICAL-1 
(4TXI, [76]) highlighting the possible actin binding site (ABS, cyan) and the PIP2 binding site (PIP2) based 
on the similarity with type 2 CH domains. Residues matching the ABS and PIP2 binding site fingerprints are 
shown in cylinders. The region corresponding to the PIP2 binding site of type 2 CH domains is shown in 
worm representation in sea green. Right panel: model of the human MICAL-1 LIM domain. Since the 
structure was determined by NMR (2C08) a single chain model was obtained with Swiss-Model [131] and 
the sequence of human MICAL-1. The residues interacting with the zinc ions (spheres, red) are shown in 
cylinders. 
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Figure 8. Structure of the Rab binding domain of human MICAL-1 and MICAL-3. Left: model of the human 
MICAL-1 Rab binding domain (ribbons) in complex with two copies of Rab10 (worms and tubes, grey, 
[69]). Some of the residues implicated in Rab10 binding [69] and those that were found to be essential for 
binding with Rab35 [32] are indicated in cylinders. Color code: ice, residues 918-993; light green, residues 
994-1059. Right: model of the human MICAL-3 Rab binding domain, which forms a dimer in the crystal 
[69]. The residues corresponding to those implicated in Rab10 interaction in the MICAL-1/Rab10 structure 
are in cylinders to show how the interface between the MICAL-3 RBD monomers overlaps with the C-
terminal Rab10 binding site of MICAL-1. The first and second half of the domain are shown as for MICAL-
1 in ice and light green, respectively. Some residues are labeled to help orientation. 
 
 
 
Figure 9. Sequence of the Rab binding domain of MICAL-1. Sequence of the 918-1067 region of human 
MICAL-1 highlighting the similarity between its N- and C-terminal halves as the result of a genetic 
duplication [69]. The regions corresponding to helices-1 (underline), -2 (double underline), and -3 (dotted 
underline) are shown along with residues that initially led to proposed the presence of a coiled-coil (grey 
highlight, [62]), some of the residues interacting with Rab10 (bold, [69]) and those that abolish or weaken 
interaction with Rab35 when mutated (blue, [32]).  
 
 
 
  
 
918                                                                              993 
KEEEMKRFCKAQTIQRRLNEIEAALRELEAEGVKLELALRR--------QSSSPEQQKKLWVGQLLQLVDKKNSLVAEEAELMI 
 
                          994                                                                   1067 
                          TVQELNLEEKQWQLDQELRGYMNREENLKTAADRQAEDQVLRKLVDLVNQRDALIRFQEERRLSELALGTGAQG 
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Figure 10. pH dependence of the steady-state kinetic parameters of the NADPH oxidase reaction catalyzed 
by human MICAL-1 forms. The steady-state kinetic parameters kcat, kcat/KNADPH and KNADPH  for the NADPH 
oxidase activity of human MICAL-1 and of the MO, MOCH, MOCHLIM truncated forms were determined 
spectrophotometrically at 25°C by varying NADPH concentration in a mixed buffer composed of 10 mM 
acetate, 5 imidazole, 5 mM Tris, (Buffer 1, ionic strength 10 mM (open circles) or of 12.5 mM formate, 5 
mM imidazole, 5 mM Tris (Buffer 2, ionic strength 12.5 mM, closed circles). The curves were drawn with 
the equations and parameters values reported in [79]. The apparent pKa values are shown in the figure. For 
clarity only the the pKa obtained with MO in Buffer 1 are shown. The figure is reprinted from [79] with 
permission from the publisher. 
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Figure 11. Model of mouse MICAL-1 MOCH in complex with actin Met44. Panels A -D depict the complex 
between mouse MICAL-1 MOCH (gold ribbons) and a fragment of an actin filament built by Alqassim et al. 
[76]. The MICAL MOCH was positioned placing the CH domain where the α-actinin CH1 domain binds to 
F-actin (dashed red line in A, dark green in B) so that the “large opening” of MO  (i.e.: the NADPH binding 
site) was towards the filament according to the MOCH structure (Figure 6B). In a series of molecular 
dynamics simulations Met44 (sticks in C and D) of one actin subunit (green) was progressively constrained 
to reach a distance of approximately 3 Å from FAD 4a position as described by [76]. For comparison Panel 
E and F have been drawn using the mouse MICAL-1 MOCH structure (4TXI, [76]) and highlighting the N-
terminal 1-85 region (blue), the β9 and β 15 strands connecting the FAD and the cap domain (dashed green), 
the 395-405 loop (dashed red), FAD (cylinders, carbon atoms cyan) and Trp400 (carbon atoms green). The 
distance between FAD-N5 and Trp400 CZ3 (which appears to occupy a position similar to that of Met44 in 
Panel D) is indicated in F. Note that in the “flavin in” conformation, the same Trp carbon atom may be 
roughly in front of FAD C9 of the dimethylbenzene ring (see Figure 5). The figures in A-D are reprinted 
from [76]with permission from the publisher. 
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Figure 12. Effect of F-actin on the time-course and extent of NADPH oxidation catalyzed by human MICAL1 
forms. MOCH (150 nM), MOCHLIM (115 nM), and full-length MICAL (1.5 µM) were incubated with 
NADPH (100 µM) in the absence (open circles) or in the presence of F-actin (5 µM, closed circles) in F-
actin stabilizing buffer at 25 °C. The traces obtained with MO are similar to those shown for  MOCH. The 
time-course of NADPH oxidation was monitored continuously by absorption spectroscopy at 340 nm. 
Reprinted from [79] with permission from the publisher. 
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Figure 13. MICAL-1 modified actin residues. The residues that were found to be modified with similar 
probability in F-actin that had been treated with human MICAL-1 in [79] are shown in spacefill on the actin 
filament structure from PDB file 3J8I [111]. A detail is shown on the right. 2-3 actin residues were found to 
be modified in each monomer. Met44 and Met47, Met269 or Met283, Met355 or Trp340 or Trp 356, Met82 
or Trp79 or Trp86 (in spacefill representation) were modified with the same probability. 
 
 
 
Figure 14. Proposed model of interaction between MICAL-1 in the active conformation and F-actin. The 
scheme explains the apparent Km value for F-actin with full length human MICAL-1, which is approximately 
10-fold higher than that measured with the other MICAL forms (see Table 3). The figure is reprinted from 
[79] with permission from the publisher. 
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Figure 15. Kinetic scheme of the activating effect of F-actin on the NADPH oxidoreductase reaction of 
MICAL MO. The scheme depicts the activating effect of F-actin on the activity of MICAL MO and MOCH 
proposed by [76] in which F-actin is treated as non-essential activator of MO reaction (see e.g.: [132]). In the 
thermodynamic scheme, K1 is the dissociation constant of the enzyme/NADPH complex; K2 is that of the 
enzyme F-actin complex. α is the factor by which F-actin modifies the Kd of the enzyme/NADPH complex: 
for no effect of actin on NADPH binding, α =1; for enhancement of binding α<1; for weakened binding α>1. 
As a consequence in the thermodynamic cycle in the scheme, binding of F-actin to the enzyme/NADPH 
complex is also modified by α. β is the factor that expresses the effect of F-actin on the reaction rate. For an 
acceleration of the reaction, β >1. According to the model proposed by ([76]) for the reaction of mouse 
MICAL-1 MO and MOCH both branches of the scheme are operative in the presence of F-actin, which has a 
different effect on MICAL-1 MO and MOCH. With MO, the data obtained by varying NADPH 
concentration at different F-actin levels were fitted with K1 =28.85 ± 2.4 µM; K3 = 9.3 ± 1.9 µM; α = 1; kcat 
= 0.069 ± 0.02 s-1; β = 4.7 ± 0.5. The corresponding data with mouse MICAL-1 MOCH were fitted with K1 
=37.7 ± 8.4 µM; K3 = 10.5 ± 3.4 µM; α = 0.16 ± 0.04; kcat = 1.66 ± 0.13 s-1; β = 7.43 ± 0.31. For human 
MICAL-1 forms only the lower branch of the scheme would be operative in the presence of F-actin (Table 
3). 
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Figure 16. Effect of F-actin on the kinetics of mouse MICAL-1 MO and MOCH. The values of apparent kcat 
for mouse MICAL-1 MO (circles, left axis) and MOCH (squares , right axis) extrapolated at infinite NADPH 
concentration in the presence of fixed F-actin levels were taken from Table 4 of [76] and plotted as a 
function of the stated F-actin concentration. The curve shows the fit to the Michaelis-Menten equation of the 
values obtained with MOCH in the presence of 2-8 µM F-actin. The Grafit program (Erythacus Software 
Ltd, UK) was used. The calculated values for the steady-state kinetic parameters were: kcat, 11.7 ± 0.9 s-1; 
Km,F-actin , 0.9 ± 0.4 µM. The large error associated with the Km value is due to the use of only three F-actin 
concentrations that are not suitably spaced to define the apparent Km in the light of its low value. The plot 
shows how the apparent kcat values measured with MO and MOCH in the presence of F-actin differ by a 
factor of ~6 but follow the same hyperbolic trend. See text. 
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Figure 17. Proposed model of the equilibria among “autoinhibited” and active conformations of MICAL. 
The “autoinhibited” conformation of MICAL-1 is depicted as a “closed” form in equilibrium with the active 
“open” conformation. The equilibrium between the forms is shifted towards the open form by activating 
proteins that bind to the C-terminus (e.g.: the cytoplasmic side of plexin or Rab) or elsewhere. Binding of 
MO to F-actin (not to scale in the figure) would be sufficient to stabilize the active (open) form. The 
interaction between F-actin and MICAL that has been activated upon complex formation with plexin or other 
proteins is not shown for clarity. The possibility that the MICAL active/inactive conformations are further 
stabilized by dimerization should not be disregarded. Thus, dimerization of the species is indicated with a 
question mark The color code is the same as that in Figure 1A. 
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